Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation

专利摘要:
PURPOSE: The present invention relates to arylcycloalkane carboxyl esters having pharmacological properties, and to processes for their preparation. CONSTITUTION: The invention relates to the use of compounds of general Formula (IA) wherein: A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and attached at a single ring carbon atom thereof; Ar is phenyl or heteroaryl having 5 or 6 ring members, R1 and R2 independently are hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R1 and R2 together form lower alkylenedioxy or optionally substituted benzo; and R3 is (i) -(CH2)nNR10, R11, in which n is 2 or 3 and R10 and R11 each are lower alkyl or R10 and R11 together with the nitrogen atom form a saturated azacyclic or azabicyclic ring system; or (ii) -(CH2)m-Q, in which m is 0 or 1 and Q is the residue of a saturated azacyclic or azabicyclic ring system coupled via a carbon atom thereof, or a pharmacologically acceptable salt thereof, for treatment of urinary incontinence or irritable bowel syndrome. The invention also relates to novel compounds encompassed by Formula (IA), pharmaceutical compositions thereof and preparation of the compounds.
公开号:KR20000029703A
申请号:KR1019997000803
申请日:1997-07-23
公开日:2000-05-25
发明作者:아케르블롬에바；하랄드손마르틴；요한손롤프；비에르레인카타리나；스죄베르그비르거；링베르그에릭；베인즈비르기타
申请人:존 헤덴스트룀；파마시아 앤드 업존 에이비；
IPC主号:

专利说明:

Arylcycloalkane carboxylic acid esters, uses thereof, pharmaceutical compositions and methods of preparation {ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION}
[2] Many arylcycloalkane carboxylic acid esters, including arylcyclopropane, arylcyclobutane, arylcyclopentane and arylcyclohexane carboxylic acid esters, are known to have anticholinergic activity. It has been suggested that some of them have pronounced antifungal or anticonvulsive activity and thus can be used as a substitute for atropine in treating sarin poisoning (sarin is an organophosphorus anticholinesterase that acts as a nerve gas). Other activities associated with such types of compounds are antipsychotics, anti-ischemic, anti-seizure and anti-dementia.
[3] Particular arylcyclopropane carboxylic esters with anticholinergic activity are described, for example, in Beres, J. A., et al., J. Pa. Acad. Sci. (1992), 66 (1), 2; US Patent No. 4,418,202; Mnjoyan, A. L., et al., Arm. Khim. Zh. (1976), 29 (2); Kuzuna, S., et al., Takeda Kenyosho Hu (1975), 34 (4), 467-73; And WO 92/02481.
[4] Arylcyclobutane carboxylic acid esters with anticholinergic activity are described, for example, in Bannard, R. A. B., et al., Can. J. Phys. Pharm. 47 (1969) 1036 (2′-diisopropylaminoethyl 1-phenylcyclobutane-carboxylic acid salt, 1′-methylpiperidyl-4 ′ 1-phenylcyclobutane-carboxylic acid salt); CH-B-240160 (diethylaminoethyl 1-phenylcyclobutylcarboxylate); Parkkari, J. H., et al., Can. J. Chem. 43 (1965) 3119 (N-methyl-4-piperidyl 1-p-methylphenylcyclobutanecarboxylate, N-methyl-4-piperidyl 1-p-methoxyphenylcyclobutanecarboxylate); And Mnoyan, S. et al., Supra (dimethylaminoethyl and diethylaminoethyl 1-benzophenylcyclobutylcarboxylate).
[5] Arylcyclopentane carboxylic acid esters having anticholinergic activity are described, for example, in Bannard, R. A. B., et al., Can. J. Chem. 40 (1962) 1909-1916; Stubbins, J. F., et al, Med. Chem. Res. 2 (1992) 384-393; JP-A-02062823; US-A-3,317,526; FR-A-1461314; FR-A-2155927; DD-A-289411 and FR-A-2168881.
[6] Arylcyclohexane carboxylic acid esters having anticholinergic activity are described, for example, in Zbigniew, J., et al., Pol. J. Pharmacol. Pharm. 35 (1983) 103-107; Tsung-Ping Su et al., Pharmacology and Exp. Therapeutics 259 (1991) 543-550; Wolinski, J., and Cessak, M., Acta Pol. Pharm. 36 (1979) 635-40; WO 92/02481 and FR-A-2155927.
[7] Summary of the Invention
[8] A limited group of arylcyclopropane, arylcyclobutane, arylcyclopentane, and arylcyclohexane carboxylic acid esters, some of which are new compounds, because these have selective antimuscarinic activity on bladder smooth muscle and intestinal muscle It has now been found by the present invention to apply to the treatment of small bowel diseases such as irritable bowel syndrome as well as to treat bladder diseases.
[9] In one aspect, the present invention provides a new arylcycloalkane carboxylic acid ester having the formula (I) or a pharmacologically acceptable salt thereof:
[10]
[11] here,
[12] A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and is bonded to its single ring carbon atom,
[13] Ar is phenyl or heteroaryl having 5 or 6 ring groups,
[14] R ₁ and R ₂ are independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R ₁ and R ₂ jointly form lower alkylenedioxy or optionally substituted benzo ,
[15] R ' ₃ is (i)-(CH ₂ ) _n NR ₁₀ , R ₁₁ , n is 2 or 3 and each of R ₁₀ and R ₁₁ is lower alkyl or R ₁₀ and R ₁₁ are saturated azacyclo or To form an azabicyclo ring system; (ii)-(CH ₂ ) _m -Q, wherein m is 0 or 1 and Q is a saturated azacyclo or azabicyclo ring system bonded by its carbon atom,
[16] Conditionally,
[17] (Iii) A is cyclopropane unsubstituted or mono-substituted by lower alkyl or lower alkenyl, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ , R ₁₁ and R ₁₀ and R ₁₁ If it is lower alkyl, R ₁₀ and R ₁₁ together contain at least 6 carbon atoms;
[18] (Ii) A is a cyclopropane ring, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ , R ₁₁ , n is 2 and R ₁₀ and R ₁₁ together with the nitrogen atom form a pyrrolidine ring Or when R ' ₃ is-(CH ₂ ) _m -Q, m is 0 and Q is a tropanyl ring, the cyclopropane ring is at least mono-substituted;
[19] (Iii) when A is an unsubstituted cyclobutane ring, Ar is phenyl, and R ₁ and R ₂ are hydrogen, then R ' ₃ is diisopropylaminoethyl, diethylaminoethyl and N-methyl-4-piperi Not a deal;
[20] (Iii) when A is an unsubstituted cyclobutane ring, Ar is phenyl, R ₁ is hydrogen and R ₂ is p-methyl or p-methoxy, then R ' ₃ is N-methyl-4-piperidyl Not;
[21] (Iii) when A is an unsubstituted cyclobutane ring, Ar is phenyl and R ₁ and R ₂ jointly form benzo, then R ' ₃ is not dimethylaminoethyl and diethylaminoethyl;
[22] (Iii) when A is a cyclopentane ring and Ar is phenyl, the cyclopentane ring is at least mono-substituted;
[23] (Iii) when A is an unsubstituted cyclohexane ring, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ R ₁₁ and R ₁₀ and R ₁₁ are lower alkyl, then R ₁₀ and R ₁₁ are taken together; Contains at least six carbon atoms; And
[24] (Iii) If A is a cyclohexane ring, Ar is phenyl, R ' ₃ is-(CH ₂ ) _m -Q and m is 0, then the cyclohexane ring is at least mono-substituted.
[25] Cycloalkane ring A may be substituted at one or more ring carbons (mono- or di-substituted at each carbon), preferably lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, cycloalkyl, lower alkenyl , Lower hydroxyalkyl, benzyloxy-lower alkyl, trifluoromethyl, hydroxy, oxo or spiro-bonded lower alkylene or lower alkylenedioxy and can be substituted with substituents or substituents individually selected.
[26] Preferably, A is a group having the general formulas II, III, IV or V below:
[27]
[28] here,
[29] R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, cycloalkyl, lower alkenyl, lower hydroxyalkyl, benzyloxy-lower Alkyl, trifluoromethyl or hydroxy, or R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ jointly form lower alkylene, lower alkylenedioxy or oxo.
[30] The conditional parts (i) to (iii) provided above for Formula I are then defined as follows:
[31] (Iii) A is a group of formula II, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ , R ₁₁ and R ₁₀ and R ₁₁ are lower alkyl, one of R ₄ and R ₅ If is hydrogen and the other is hydrogen, lower alkyl or lower alkenyl, then R ₁₀ and R ₁₁ together contain at least 6 carbon atoms;
[32] (Ii) A is a group of formula II, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ , R ₁₁ , n is 2 and R ₁₀ and R ₁₁ are pyrrolidin together with the nitrogen atom; When a ring is formed or R ' ₃ is-(CH ₂ ) _m -Q, m is 0 and Q is a trofanyl ring, at least one of R ₄ and R ₅ is not hydrogen;
[33] (Iii) when A is a group of the general formula III, Ar is phenyl and R ₁ , R ₂ , R ₄ , R ₅ , R ₆ and R ₇ are hydrogen, R ' ₃ is diisopropylaminoethyl, diethyl Not aminoethyl and N-methyl-4-piperidyl;
[34] (Iii) if A is a group of the general formula III, Ar is phenyl, R ₁ , R ₄ , R ₅ , R ₆ and R ₇ are hydrogen and R ₂ is p-methyl or p-methoxy, then R ' ₃ is not N-methyl-4-piperidyl;
[35] (Iii) if A is a group of the general formula III, Ar is phenyl, R ₁ and R ₂ jointly form benzo, and R ₄ , R ₅ , R ₆ and R ₇ are hydrogen, then R ' ₃ is dimethyl; Not aminoethyl and diethylaminoethyl;
[36] (Iii) if A is a group of formula IV and Ar is phenyl then at least one of R ₄ , R ₅ , R ₆ and R ₇ is not hydrogen;
[37] (Iii) A is a group of formula V, Ar is phenyl, R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are hydrogen, and R ' ₃ is-(CH ₂ ) _n NR ₁₀ If R ₁₁ and R ₁₀ and R ₁₁ are lower alkyl, then R ₁₀ and R ₁₁ together contain at least 6 carbon atoms;
[38] (Iii) when A is a group of general formula V, Ar is phenyl, R ' ₃ is-(CH ₂ ) _m -Q and m is 0, then R ₄ , R ₅ , R ₆ , R ₇ , R ₈ And at least one of R ₉ is not hydrogen.
[39] One subgroup of compounds having Formula I consists of arylcyclopropane carboxylic acid esters having the following Formula I (II) (ie, when the A group of Formula I is a group of Formula II above):
[40]
[41] Wherein Ar, R ₁ , R ₂ , R ' ₃ , R ₄ and R ₅ are as defined above, including the conditional parts (i) and (ii).
[42] In the more limited arylcyclopropane carboxylic ester group within this subgroup, R ₁₀ and R ₁₁ are lower alkyl in total having at least 6 carbon atoms when R ′ ₃ is — (CH ₂ ) _n NR ₁₀ R ₁₁ .
[43] In another limited group of compounds within this subfamily, at least one of R ₄ and R ₅ is not hydrogen.
[44] Another subgroup of compounds having Formula I consists of arylcyclobutane carboxylic acid esters having Formula I (III) (ie where the A group of Formula I is a group of Formula III above):
[45]
[46] Here, including conditional parts (i) to (V), Ar, R ₁ , R ₂ , R ' ₃ and R ₄ to R ₇ are as defined above.
[47] In the more limited arylcyclobutane carboxylic ester group within this subgroup, at least one of R ₄ , R ₅ , R ₆ and R ₇ is not hydrogen.
[48] In another limited group of compounds within this subgroup, R ' ₃ is-(CH ₂ ) _m -Q, m is 0 or 1 and Q is a saturated azabicyclo ring.
[49] In another limited group of compounds within this subfamily, R ' ₃ is-(CH ₂ ) _m -Q and m is 1.
[50] In still other limited group of compounds within this subgroup, if R ' ₃ is-(CH ₂ ) _n NR ₁₀ R _11, then R ₁₀ and R ₁₁ in combination are lower alkyls having at least six carbon atoms.
[51] Another subgroup of compounds having Formula I consists of arylcyclopentane carboxylic acid esters having Formula I (IV) (ie where the A group of Formula I is a group of Formula IV above):
[52]
[53] Here, including the conditional part, Ar, R ₁ , R ₂ , R ' ₃ and R ₄ to R ₇ are as defined above.
[54] In the more limited group of arylcyclopentane carboxylic acid esters within this subgroup, if R ' ₃ is-(CH ₂ ) _n NR ₁₀ R _11, then R ₁₀ and R ₁₁ together are lower alkyl having at least 6 carbon atoms.
[55] Another subgroup of compounds having Formula I consists of an arylcyclohexane carboxylic acid ester having Formula I (V) (ie where the A group of Formula I is a group of Formula V above):
[56]
[57] Here, including the condition (ⅶ) to _{(ⅷ), Ar, R 1} , R 2, R '3 and R ₄ to R ₉ are as defined above.
[58] In the more limited arylcyclohexane carboxylic ester group within this subgroup, at least one of R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ is not hydrogen.
[59] In another limited group of compounds within this subfamily, if R ' ₃ is-(CH ₂ ) _n NR ₁₀ R _11, then R ₁₀ and R ₁₁ together are lower alkyl having at least six carbon atoms.
[60] In another aspect, the present invention provides a compound having Formula I above for therapeutic use, in particular for antagonizing muscarinic receptors, more particularly for treating urinary incontinence-related diseases or for treating irritable bowel syndrome (IBS). .
[61] In another aspect, the present invention provides a pharmaceutical composition comprising, as an active ingredient, one or more compounds having formula (I) above, preferably with a pharmaceutically acceptable carrier, if desired, with other pharmacologically active agents. do.
[62] In another aspect, the present invention provides a method of treating a living body suffering from a disease associated with urinary incontinence, which method comprises administering to the living body an effective amount of a compound having formula (IA) or a pharmacologically acceptable salt thereof Steps include:
[63]
[64] here,
[65] A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and is bonded to its single ring carbon atom,
[66] Ar is phenyl or heteroaryl having 5 or 6 ring groups,
[67] R ₁ and R ₂ are independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R ₁ and R ₂ jointly form lower alkylenedioxy or optionally substituted benzo ,
[68] R ₃ is (i)-(CH ₂ ) _n NR ₁₀ , R ₁₁ , where n is 2 or 3 and R ₁₀ and R ₁₁ are each lower alkyl, or R ₁₀ and R ₁₁ are saturated azacyclo or To form an azabicyclo ring system; (ii)-(CH ₂ ) _m -Q wherein m is 0 or 1 and Q is a residue of a saturated azacyclo or azabicyclo ring system bonded by its carbon atom.
[69] Cycloalkane ring A is preferably at least one ring carbon, preferably lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, cycloalkyl, lower alkenyl, lower hydroxyalkyl, benzyloxy-lower alkyl, trifluoromethyl, Or a substituent or substituents independently selected from hydroxy, oxo or spiro-bonded lower alkylene or lower alkylenedioxy (mono- or di-substituted at each carbon).
[70] Preferably, the A group of formula IA is a group having the general formulas II, III, IV or V below:
[71]
[72] Wherein R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, cycloalkyl, lower alkenyl, lower hydroxyalkyl, benzyloxy -Lower alkyl, trifluoromethyl or hydroxy or R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ jointly form lower alkylene, lower alkylenedioxy or oxo.
[73] In another aspect, the present invention provides a method of treating a living body suffering from a disease associated with irritable bowel syndrome (IBS), which method comprises administering to the living body an effective amount of a compound having Formula IA as defined above. Steps.
[74] In another aspect, the present invention provides a pharmaceutical composition for treating a disease associated with urinary incontinence, wherein the composition comprises a compound having one or more of the above formulas (IA) as the active ingredient, preferably pharmaceutically acceptable Together with the carrier, if desired together with its pharmacologically active agent.
[75] In another aspect, the present invention provides a pharmaceutical composition for treating irritable bowel syndrome (IBS), the composition comprising a compound having one or more of the above formulas (IA) as the active ingredient, preferably pharmaceutical Together with an acceptable carrier, if desired together with its pharmacologically active agent.
[76] In another aspect, the present invention provides the use of a compound having formula (IA), for the manufacture of a medicament for the treatment of urinary incontinence related diseases.
[77] In another aspect, the invention provides the use of a compound having formula (IA) for the manufacture of a medicament for the treatment of irritable bowel syndrome (IBS).
[78] In another aspect, the present invention provides a method for preparing a compound having formula (I).
[1] The present invention relates to arylcycloalkane carboxylic acid esters having pharmacological properties, and methods for their preparation. The present invention is also directed to pharmaceutical compositions containing arylcycloalkane carboxylic acid esters, arylcycloalkane carboxylic acid esters, respectively, as well as methods of treating diseases associated with urinary incontinence and irritable bowel syndrome (IBS), respectively, as well as urinary incontinence and The present invention relates to a method for preparing a pharmaceutical composition for treating diseases associated with irritable bowel syndrome (IBS).
[79] In the compounds having formulas (I) and (IA) as defined above, the term lower alkyl, individually and jointly (also with alkylene), means 1-6 carbon atoms, in particular 1-5 carbon atoms, preferably 1-4 carbon sources It is meant to include straight and branched, saturated hydrocarbon groups having a ruler. Typical alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, n-pentyl, n-hexyl and isomers thereof.
[80] The term lower alkenyl includes straight and branched hydrocarbon groups having 2-6 carbon atoms, in particular 2-5 carbon atoms, preferably 2-4 carbon atoms, including one or more unsaturateds, individually and jointly Means that. Typical alkenyl groups are ethenyl, propenyl, butenyl, pentenyl, hexenyl, methylpropenyl, ethylbutenyl and isomeric forms thereof.
[81] The term lower alkoxy, individually and jointly, means including straight and branched, saturated alkoxy groups having 1-6 carbon atoms, in particular 1-5 carbon atoms, preferably 1-4 carbon atoms.
[82] Cycloalkyl is preferably C _3-8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.
[83] Typical heteroaryl groups are thiophene, furan, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine. Preferred heteroaryl groups are 2-or 3-thienyl, 2-or 3-furanyl and 2-, 3-or 4-pyridine.
[84] Halo includes fluoro, chloro, bromo and iodo, with fluoro, chloro or bromo being preferred.
[85] Lower alkylenedioxy is preferably methylenedioxy.
[86] The benzo is preferably 2, 3-benzo or 3, 4-benzo. When benzo is substituted, it may be substituted at one or more of the ortho-, meta- or para- positions. It is preferred to be di- or mono-substituted, more preferably mono-substituted.
[87] If R ' ₃ or R ₃ comprises a saturated azacyclo or azabicyclo ring system, then its nitrogen atom has tertiary properties either by the presence of the bridging ends or by substitution with the preferred N-substituents with lower alkyl and lower alkenyl. Will have.
[88] Typical azacyclo and azabicyclo rings are piperidine, pyrrolidine, azanorbornane, azacycloheptane, quinuclidin, isoquinuclidin, tropane, azabicyclo [3.2.1] octane, azabicyclo [2.2 .1] heptane, 2-azabicyclo [3.2.1] octane, azabicyclo [3.2.1] octane, azabicyclo [3.3.0] octane, azabicyclo [3.2.2] nonane, azabicyclo [3.3.1] Nonan.
[89] The azacyclo or azabicyclo ring may be mono- or independently di-substituted by lower alkyl, lower alkenyl, halo, lower alkoxy or hydroxy, preferably by methyl, methoxy or hydroxy, at any carbon atom Can be.
[90] When R ' ₃ or R ₃ is-(CH ₂ ) _n NR ₁₀ R _11, n is preferably 2, and R' ₃ or R ₃ is-(CH ₂ ) _m -Q, m = 0 and Q is an azabicyclo ring In this case, the nitrogen atom of the azabicyclo ring is preferably spaced one carbon atom from the bonded carbon atom.
[91] If R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are individual groups, selected from hydrogen, lower alkyl, lower alkoxy, methoxymethyl, benzyloxymethyl, ethenyl, propenyl and trifluoromethyl It is desirable to. When R ₄ and R ₅ , R ₆ and R ₇ or R ₈ and R ₉ jointly form lower alkylene or lower alkylenedioxy, it is preferred to select from dimethylene, trimethylene and ethylenedioxy.
[92] In a preferred subgroup of compounds having formula (I) and (IA), respectively,
[93] Ar is phenyl, 2- or 3- thienyl, 2- or 3-furanyl or 2-, 3- or 4- pyridine; And / or
[94] R ₁ and R ₂ are independently hydrogen, fluoro, chloro, bromo, C _1-4 alkyl, C _1-4 alkoxy, methoxymethyl, phenoxymethyl, vinyl, allyl, trifluoromethyl; And / or
[95] R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, C _1-4 alkyl, C _1-4 alkoxy, methoxymethyl, benzyloxymethyl, vinyl, allyl, trifluoromethyl Or otherwise R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ jointly form dimethylene, trimethylene, tetramethylene or ethylenedioxy.
[96] Formulas I and IA include enantiomeric and racemic forms. The compounds of formulas I and IA may also be in the form of salts suitable for pharmacological use. They may form salts with physiologically acceptable acids, organic and inorganic acids, and the present invention includes not only their salts but also free bases. Examples of such salts include hydrochloride, hydrobromide, hydrogen fumarate and the like.
[97] Typical compounds having Formulas I and IA include the following:
[98] 2- (diisopropylamino) ethyl 1-phenyl-2-trans-methoxy-methylcyclopropanecarboxylate;
[99] 3-quinucridinyl 1-phenylcyclopropanecarboxylate;
[100] 2- (diisopropylamino) -ethyl 1-phenyl-cis-2-methoxymethylcyclopropanecarboxylate;
[101] 2- (diisopropylamino) ethyl 1-phenyl-3-dimethylcyclobutanecarboxylate;
[102] 3-quinucridinyl 1-phenylcyclobutanecarboxylate;
[103] 2- (diisopropylamino) ethyl 1-phenyl-3-cis-methylcyclobutanecarboxylate;
[104] 2- (diisopropylamino) ethyl 1-phenylcyclopentanecarboxylate;
[105] 3-quinucridinyl 1-phenylcyclopentanecarboxylate;
[106] 2- (diisopropylamino) ethyl 1-phenylcyclohexanecarboxylate; And
[107] 3-quinucridinyl 1-phenylcyclohexanecarboxylate.
[108] The compounds having the formulas (I) and (IA) can be prepared by conventional methods or by methods analogous to the conventional methods, in particular according to the following methods a) and b) or by methods analogous to this method.
[109] Method a:
[110] A compound having the following formula (VI), or a reaction derivative thereof having a carboxyl group activated, is reacted with a compound having the formula (VIIa) or a compound having the formula (VIIa) in the presence of a strong base.
[111]
[112] Wherein R ₁ , R ₂ , A and Ar are as defined above.
[113] HO-R ₃
[114] Where R ₃ is as defined above.
[115] Cl-R ₃
[116] Where R ₃ is as defined above.
[117] Method b:
[118] In compounds having the formula VIIa, at least one of A ', R' ₁ and R ' ₂ is converted to groups A, R ₁ and R ₂ , respectively.
[119]
[120] Wherein R ' ₃ is as defined above and A', R ' ₁ and R' ₂ each represent A, R ₁ and R ₂ as defined above or can be converted to A, R ₁ and R ₂ respectively Indicates.
[121] Converting group A 'to group A usually involves converting one or more substituents on the cycloalkane ring. In particular, A 'is a group having the following general formulas IIa, IIIa, IVa or Va:
[122]
[123] Wherein R ' ₄ , R' ₅ , R ' ₆ , R' ₇ , R ' ₈ and R' ₉ represent R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ , respectively, or R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ which can be converted into groups, wherein one of the groups R ' ₄ , R' ₅ , R ' ₆ , R' ₇ , R ' ₈ and R' ₉ Or more are converted to the groups R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ , respectively.
[124] When the method a) is carried out by reacting a compound having the formula VI with a compound having the formula VIIa, the compound having the formula VI is preferably converted into a reactive derivative, such as an anhydride or an acid chloride. In the latter case (eg further described in Example 4 below) the reaction may be carried out with an inert organic solvent or mixture of solvents such as benzene or toluene. Suitable temperature ranges for the reaction are from room temperature to about 100 ° C. The resulting product can be separated by conventional methods.
[125] Acid chlorides of the compounds having formula VI can be prepared by reacting a compound having formula VI with thionyl chloride. The resulting acid chloride need not be separated off but can be added directly to the reaction mixture.
[126] The reaction of a compound of formula (VIIa) with a compound of formula (VI) (for example, further described in Example 7 below) may be carried out using an aprotic dipolar solvent or a mixture of solvents such as dimethylformamide, acetonitrile or dimethyl It can be performed with sulfoxide. As a strong base, sodium hydride or potassium tert-butylate can also be used. Suitable temperature ranges for the reaction are from about 0 to about 100 ° C. The resulting product can be separated by conventional methods.
[127] The reaction between the compound having the formula VI in acid form and the compound having the formula VIIa is carried out in the presence of a dehydrating agent, preferably carbodiimide, such as dicyclohexylcarbodiimide (DCC), as a catalyst and a base.
[128] In process b) (for example, as further described in Example 9 below), for example, compounds of formula (I) or (IA) having hydroxy-containing substituents can be obtained by hydrogenation of the corresponding benzyloxy compounds . In addition, methods b) is a group _{R 4, R 5, R 6} , R 7, R 8 and R ₉ of one or the above other group or of each group _{R 4, R 5, R 6} , R 7, R 8 and R ₉ Conversion to a nitro group to an amino group, for example by hydrogenation, or reduction of an oxo group to a hydroxyl group.
[129] If the group A in formula (I) or (IA) is a group having the general formula (II) as defined above, the corresponding arylacetic acid ester is reacted with a suitable chloroepoxyalkane to form a hydroxyl-containing trans-substituent and the hydroxy group is subjected to esterification reaction The trans-substituted starting material of can be prepared, Route A (see eg Example 1 below). To prepare a cis-substituted starting material of formula VI, substitute for corresponding arylnitrile in place of arylphenylcarboxylic acid ester in the above procedure, route B (see eg Example 3 below). The reaction pathways A and B are schematically shown in Reaction Scheme I provided at the end of the specification.
[130] By converting one or more substituents on the cyclopropane ring, such as substituents R ₄ or R ₅ as defined above, to convert the arylcyclopropane carboxylic acid having formula VI to another arylcyclopropane carboxylic acid having formula VI Can be.
[131] If group A in formula (I) or (IA) is a group having general formula (III), the starting material of formula (VI) can be prepared by any of the routes A to E shown in Scheme II, for example.
[132] In the route A, arylacetonitrile is reacted with 1,3-dibromopropane to give arylcyclobutaneacetonitrile and then hydrolyzed to form arylcyclobutanecarboxylic acid having formula VI (Examples 9-9 below). Described in section 26).
[133] For routes B and C, arylacetonitrile can be selected from di-0-p-toluenesulfonyl-1, 3-propanediol (path B) or 3-bromo-Op-toluenesulfonyl-1-propanol (path C) To 1-phenylcyclobutaneacetonitrile and then hydrolyzed to form arylcyclobutanecarboxylic acid having formula VI (Path B is described in Examples 27-28 below and Path C is Example 29- Described in section 31).
[134] For route D, the arylacetic acid ester is reacted with 1,3-dibromopropane to give 1-phenylcyclobutanecarboxylic acid ester, which is then hydrolyzed to form arylcyclobutanecarboxylic acid having formula VI ( Described in Examples 32-33 below).
[135] For Route E, 1-cyano-1-phenyl-3-oxycyclobutane is reacted with alkyltriphenylphosphonium bromide (Bitch reaction) to give 1-phenyl-3-alkylenecyclobutane-acetonitrile And then hydrolyzed to form an arylcyclobutanecarboxylic acid having formula VI (as described in Example 34).
[136] Arylcyclo having Formula VI by converting one or more substituents on the cyclobutane ring, such as R ₁ , R ₂ , R ₄ , R ₅ , R ₆ or R ₇ as defined above (as described in Example 35) Butanecarboxylic acid may be converted to another arylcyclobutanecarboxylic acid having the formula (VI).
[137] If the group A in formula (I) or (IA) is a group having the general formula (IV), starting materials of formula (VI) can be prepared, for example, by route A or B shown in Scheme III.
[138] For route A, arylacetonitrile is reacted with 1,4-dibromobutane to yield arylcyclopentaneacetonitrile and then hydrolyzed to form arylcyclopentanecarboxylic acid having Formula VI (Examples 94 and As described in 95).
[139] For route B, arylacetonitrile is reacted with di-Op-toluenesulfonyl-1,4-butanediol to give 1-phenylcyclopentaneacetonitrile, which is then reacted to form an arylcyclopentanecarboxylic acid having formula VI. Disintegrate (as described in Example 96 below).
[140] An arylcyclopentanecarboxylic acid having the formula (VI) is converted to one or more substituents on the cyclopentane ring, such as R ₁ , R ₂ , R ₄ , R ₅ , R ₆ or R ₇ as defined above. It can be converted into another arylcyclopentanecarboxylic acid having.
[141] If group A in formula (I) or (IA) is a group having general formula (V), for example, starting materials of formula (VI) may be prepared by any of the routes A to C shown in Scheme IV.
[142] For route A, arylcyclohexanonecarbonitrile is reduced with the corresponding alcohol and then alkylated and hydrolyzed to form an arylcyclohexanecarboxylic acid having formula VI (as described in Example 113 below).
[143] In route B, the oxo group of the arylcyclohexanonecarbonitrile is first protected by reacting with ethylene glycol. The nitrile is then hydrolyzed with carboxylic acid followed by deprotection of the oxo group to form an arylcyclohexanecarboxylic acid having formula VI (as described in Example 114 below).
[144] In the route C, arylacetonitrile is reacted with di-Op-toluenesulfonyl-1,5-pentanediol to give 1-phenylcyclohexaneacetonitrile, followed by the formation of an arylcyclohexanecarboxylic acid having the formula VI. Dissolve (as described in Examples 115 and 116 below).
[145] Arylcyclohexanecarboxyl having the formula VI by converting one or more substituents on the cyclohexane ring, such as R ₁ , R ₂ , R ₄ , R ₅ , R ₆ , R ₇ , R ₈ or R ₉ as defined above The acid can be converted to another arylcyclohexanecarboxylic acid having the formula VI.
[146] Racemic compounds having formulas (I) and (IA) can be separated using known methods, such as various resolving acids. Separation acid salt crystallization of any suitable conventional inert organic solvent and compounds having formulas (I) and (IA), preferably at temperatures up to the boiling point of the solvent -20 ° C, may result. Typical solvents are ethanol, 1-propanol, 2-propanol, acetone, diethyl ether and ethyl acetate. Mixtures of water and solvents can also be used.
[147] Racemates can also be separated by various chromatographic techniques, such as separation of diastereomeric mixtures, separation of chiral counterions in chiral stationary or mobile phases.
[148] All of the above described methods, including the cleavage of racemates, can optionally be carried out in the presence of a catalyst which is known to be useful in the process.
[149] In general, the compounds of the present invention are characterized by the pharmacological activity described above, which compounds are useful for neutralizing precursor physiological abnormalities in humans or animals. An effective amount of the pharmacologically active compound of the invention may be administered in any of several ways, for example orally in the form of a capsule or tablet, parenterally, or in the form of a sterile solution, suspension, emulsion, small pill inoculation. Can be administered to humans or animals. One route of oral administration is intravenous, sublingual, subcutaneous, intramuscular, intraperitoneal, intradermal, bladder, urethral and intranasal administration. Other dosage forms are vaginal, rectal and topical administration, for example in the form of ointments, suppositories, powders, plasters, nebulizers and intravaginal devices.
[150] Usually pharmaceutical compositions are prepared from pre-measured amounts of one or more of the compounds having Formula I or IA above. Such formulations may or may not be accompanied by any one of a variety of pharmaceutically acceptable excipients or carriers, but preferably include powders, syrups, suppositories, ointments, solutions, pills, capsules, small pills or tablets, It may take the form of a suspension, an emulsion, an oil solution and the like.
[151] When mixed with pharmaceutical excipients or carriers, the active ingredient usually comprises from about 0.01% to about 75% by weight of the composition, usually from about 0.05% to about 15% by weight. Carriers such as starch, sugar, talc, mainly used in synthetic and natural rubber, water, and the like may also be used in such compositions. Binders such as polyvinylpyrrolidone, and lubricants such as sodium stearate may also be used to form the tablets. Disintegrants such as sodium carbonate may also be included in the tablet.
[152] Although a relatively small amount of the active substance of the invention, for example as little as 0.5 milligrams, may be used when administered to a subject with a relatively small body weight, the unit dosage is preferably 2 milligrams or more, 10, 20 Even higher doses are preferred, depending on the subject to be treated and the particular outcome desired, as will be apparent to those skilled in the art, of course, 50 or 100 milligrams. A wider range would be 1 to 1000 milligrams per unit dose.
[153] Thus, the present compounds having formulas (I) and (IA) can be used in amounts of 1 to 1000 milligrams, preferably from 2 to 250 milligrams / day / subject or patient divided into 1 to 4 doses for a suitable period of time depending on the subject to be treated and the type of subject. May be administered.
[154] The following examples are intended to illustrate the present invention, but not to limit the scope thereof. The structure of the prepared compound was confirmed by NMR and elemental or titration analysis. NMR data were recorded using a JEOL 270 MHz or Varian 500 MHz instrument. Elemental analysis was performed by Microchemie Abbey, Uppsala, Sweden. Given the melting point, Bucci (B chi) measured on a 530 instrument and was not calibrated.
[155] I. Arylcyclopropane Carboxylic Acid Ester
[156] Example 1 (Departure Material)
[157] 1 -Phenyl-2-trans-methoxymethylcyclopropanecarboxylic acid
[158] Ethyl phenylacetic acid salt (0.10 mol) dissolved in DMF (80 mL) was added to NaH (60% dispersion in mineral oil, 0.10 mol) at ambient temperature for 30 minutes. The mixture was cooled to 0 ° C. and then epichlorohydrin (0.10 mol) in DMF (20 mL) was added for 30 minutes. Additional NaH (0.10 mol) was used. The reaction mixture was partitioned between toluene and H ₂ O. The organic layer was washed three times with 1 M NaOH, dried (MgSO ₄ ) and evaporated. Purification on silica gel using 90:10 petroleum ether-EtOAc afforded 2.8 g (13%) of ethyl 1-phenyl-2-trans-hydroxymethylcyclopropane-carboxylate.
[159] A solution of methyl iodide (10 mmol) and ethyl 1-phenyl-2-trans-hydroxymethylcyclopropanecarboxylate (5 mmol) in DMF (5 mL) at ambient temperature for 15 minutes was treated with NaH (60%, 15 mmol). Was added. After stirring for 1 hour, the reaction mixture was partitioned between toluene and H ₂ O. The organic layer was dried (MgSO ₄ ) and evaporated to give 0.8 g. Chromatography on silica gel using 90:10 hexanes-EtOAc gave 0.47 g (40%); ¹ H NMR (CDCl ₃ ), δ 1.15 (t, 3H), 1.22 (dd, 1H), 1.75 (dd, 1H), 2.17 (m, 1H), 2.91 (dd, 1H), 3.06 (dd, 1H) , 3.19 (s, 3 H), 4.07 (m, 2 H), 7.32 (m, 5 H).
[160] The obtained ethyl 1-phenyl-2-trans-methoxymethyl-cyclopropanecarboxylate (1.9 mmol) was refluxed with KOH (10 mmol) in ethylene glycol (5 mL) for 3 hours and then cooled to room temperature, toluene And H ₂ O were added and the layers were separated. After the aqueous layer was acidified and extracted with toluene, the organic layer was dried (MgSO ₄ ) and concentrated to afford the title carboxylic acid.
[161] Example 2 (Departures)
[162] 1-phenyl-2-trans-benzyloxymethylcyclopropanecarboxylic acid
[163] For 15 minutes at ambient temperature, the ethyl 1-phenyl-2-trans-hydroxymethylcyclopropanecarboxylate (6.8 mmol) obtained in Example 1 was dissolved in DMF (10 mL) together with benzyl chloride (8 mmol). Then added to NaH (60% dispersion in mineral oil, 10 mmol). After stirring for 1 hour, the reaction mixture was partitioned between toluene and H ₂ O as a result of decomposition of excess hydride by addition of EtOH. The organic layer was dried (MgSO ₄ ) and evaporated. Chromatography of the residue on silica gel using 19: 1 toluene-EtOAc as eluent gave 1.0 g (47%); ¹ H NMR (CDCl ₃ ) δ 1.16 (t, 3H), 1.22 (dd, 1H), 1.75 (dd, 1H), 2.24 (m, 1H), 2.95 (dd, 1H), 3.27 (dd, 1H) , 4.07 (m, 2 H), 4.30 (m, 2 H), 7.32 (m, 10 H).
[164] The ethyl 1-phenyl-2-trans-benzyloxymethylcyclopropanecarboxylate (3.2 mmol) obtained was hydrolyzed in a similar manner as in Example 1 to give the title compound.
[165] Example 3 (Departures)
[166] 1-Phenyl-2-cis-methoxymethylcyclopropanecarboxylic acid
[167] A solution of phenylacetonitrile (30 mmol) and epichlorohydrin (30 mmol) in DMF (40 mL) was added to NaH (60% dispersion in mineral oil, 0.10 mol) at 0 ° C. for 15 minutes. Methyl iodide (30 mmol) was added while raising the temperature to room temperature. After 30 minutes of stirring, H ₂ 0 was added to extract the mixture with toluene. The organic layer was dried (Na ₂ SO ₄ ) and evaporated. Chromatography on silica gel with 90:10 hexanes-EtOAc as eluent gave hydrolyzed 1-phenyl-2-cis-methoxymethylcyclopropaneacetonitrile in a similar manner as described in Example 1. The crude product obtained was recrystallized from toluene-hexane to give 1.1 g (28%) of the title compound; ¹ H NMR (CDCL ₃ ) δ 1.44 (dd, 1H), 1.68 (dd, 1H), 1.95 (m, 1H), 3.38 (s, 3H), 3.63 (t, 1H), 3.56 (dd, 1H), 7.34 (m, 5 H), 10-12 (br, 1 H).
[168] Example 4
[169] 2- (diisopropylamino) ethyl 1-phenyl-2-trans-
[170] Methoxymethylcyclopropanecarboxylate hydrochloride
[171] 1-phenyl-2-trans-methoxymethylcyclopropanecarboxylic acid (1.9 mmol) obtained in Example 1 was refluxed with SOCl ₂ (5 ml). After 0.5 h, the reaction mixture was evaporated and the residue was taken up in toluene. 2 -diisopropylaminoethanol (3.8 mmol) was added and the mixture was stirred at rt overnight. The reaction mixture was filtered through a silica gel layer and then evaporated. The residue was dissolved in Et ₂ 0 and HCl (g) / Et ₂ 0 was added to crystallize the product to give 0.22 g (31%) of the title compound; Melting point 116-118 ° C .; ¹ H NMR (CD ₃ OD) δ 1.20 (m, 12H), 1.34 (dd, 1H), 1.73 (dd, 1H), 2.18 (m, 1H), 2.78 (dd, 1H), 3.16 (s, 3H) , 3.22 (dd, 1H), 3.36 (t, 2H), 3.57 (m, 2H), 4.34 (m, 2H), 7.37 (m, 5H). Anal (C ₂₀ H ₃₁ NO ₃ · HCl) C, H, N.
[172] Example 5
[173] 2- (diisopropylamino) ethyl 1-phenyl-2-trans-
[174] Benzyloxymethylcyclopropanecarboxylate hydrochloride
[175] From the starting materials prepared in Example 2, the title compounds were prepared in a similar manner as described in Example 4. It was reacted with SOCl ₂ for 1 hour at room temperature. 0.5 g (35%) was obtained; Melting point 117-120 ° C .; ¹ H NMR (CD ₃ 0D) δ 1.20 (m, 12H), 1.33 (dd, 1H), 1.75 (dd, 1H), 2.23 (m, 1H), 2.86 (t, 1H), 3.28-3.42 (m, 3H), 3.55 (m, 2H), 4.20-4.40 (m, 4H), 7.20-7.50 (m, 10H). Anal (C ₂₆ H ₃₅ N0 ₃ · HCl) C, H, N.
[176] Example 6
[177] 3-quinucridinyl 1-phenylcyclopropanecarboxylate hydrochloride
[178] The title compound was prepared in a similar manner to that described in Example 4. The 1-phenylcyclopropanecarbonyl chloride obtained after the chlorination step was reacted with 3-quinucridinol at 80 ° C. for 21 hours. The reaction mixture was filtered and chromatographed on silica gel using 95: 5 toluene-Et ₃ N as eluent. Yield was 0.76 g (40%); Melting point 229-233 deg. ¹ H NMR (D ₂ 0) δ 1.42-1.48 (m, 2H), 1.72-1.78 (m, 2H), 1.81-1.98 (m, 3H), 2.10 (m, 1H), 2.40 (m, 1H), 3.14 (m, 1H), 3.25-3.41 (m, 4H), 3.71 (m, 1H), 5.17 (m, 1H), 7.44 (m, 1H), 7.49 (m, 2H), 7.55 (m, 2H) . Analysis _{(C 17 H 21 NO 2 ·} HCl) C, H, N.
[179] Example 7
[180] 2- (diisopropylamino) ethyl 1-phenyl-cis-2
[181] Methoxy-Methylcyclopropanecarboxylate Hydrochloride
[182] A solution of 1-phenyl-cis-2-methoxymethylcyclopropylcarboxylic acid (1.5 mmol) in DMF (3 mL) (obtained in Example 3) was dissolved at room temperature in NaH (60% dispersion in mineral oil, 20 mmol, hexane). 2 washes). After 30 minutes, N, N-diisopropyl-2-chloroethylamine (1.8 mmol) was added. After 2 hours the reaction mixture was partitioned between H ₂ O and toluene. The organic layer was passed through a short layer of silica gel using 90:10 toluene-EtOAc as eluent. The pooled fractions were concentrated and dissolved in Et ₂ 0-hexane and HCl (g) / Et ₂ 0 was added to crystallize the title compound. 0.20 g (56%) was obtained; Melting point 46-50 ° C .; ¹ H NMR (CD ₃ 0D) δ 1.17 (m, 12H), 1.38 (dd, 1H), 1.71 (dd, 1H), 2.03 (m, 1H), 3.33 (m, 2H), 3.37 (s, 3H) , 3.55 (m, 3H), 3.82 (dd, 1H), 4.35 (m, 2H) and 7.34 (m, 5H). Anal (C ₂₀ H ₃₁ N0 ₃ · HCl) C, H, N.
[183] Example 8
[184] 2- (diisopropylamino) ethyl 1-phenyl-2-trans-
[185] Hydroxymethylcyclopropanecarboxylate hydrochloride
[186] 2-(diisopropylamino) ethyl 1 -phenyl-2-trans-benzyloxymethylcyclopropanecarboxylate (0.32 g, 0.79 mmol) obtained in Example 5 was dissolved in H0Ac (10 mL). Charcoal (50 mg) containing palladium (10%) was added and the mixture was then hydrogenated at atmospheric pressure for 16 hours. The catalyst was filtered off and the solvent was evaporated. The residue was partitioned between toluene and 1 M Na0H. The aqueous layer was extracted several times with toluene. The combined organic layers were dried (MgS0 ₄ ) and concentrated to give a free base dissolved in isopropanol and Et ₂ 0, and 0.15 g (54%) of the title compound was added dropwise with HCl (g) / Et ₂ 0. Obtained; Melting point 105-107 캜; ¹ H NMR (CD ₃ 0D) δ 1.20 (m, 12H), 1.32 (dd, 1H), 1.73 (dd, 1H), 2.16 (m, 1H), 3.16 (d, 2H), 3.35 (t, 2H) , 3.57 (m, 2H), 4.35 (m, 2H), 7.35 (m, 5H). Anal (C ₁₉ H ₂₉ NO ₃ HCl) C, H, N.
[187] II. Arylcyclobutane Carboxylic Acid Ester
[188] Example 9 (Departures)
[189] 1-(2-bromophenyl) cyclobutanecarboxylic acid
[190] NaH (80% dispersion in mineral oil, 127 mmol) was washed several times with n-pentane and suspended in DMF (50 mL). A mixture of 2-bromophenylacetonitrile (51 mmol) and 1,3-dibromopropane (51 mmol) in DMF (50 mL) was added dropwise to the ice-cold mixture. The reaction mixture was stirred at rt for 3 h. Excess hydride was cracked by the careful addition of H ₂ O. Extraction with toluene and drying the organic layer (MgS0 ₄ ) followed by evaporation of the solvent gave 1- (2-bromophenyl) -cyclobutaneacetonitrile, which was KOH (210 mmol) in ethylene glycol (50 mL) for 4 hours. ) With reflux. The resulting solution was cooled to room temperature, and toluene and H ₂ 0 were added to separate the layers. The aqueous layer was acidified and extracted with Et0Ac. The organic layer was dried (MgSO ₄ ) and concentrated to afford the desired product. Yield was 8.5 g (65%); ¹ H NMR (CDCl ₃ ) δ 1.80-1.93 (m, 1H), 2.20-2.40 (m, 1H), 2.54-2.65 (m, 2H), 2.86-2.96 (m, 2H), 7.07-7.15 (m, 1H), 7.29-7.37 (m, 2H), 7.53 (d, 1H).
[191] Example 10 (Departures)
[192] 1-(4-bromophenyl) cyclobutanecarboxylic acid
[193] The title compound was prepared from 4-bromophenylacetonitrile and 1,3-dibromopropane in a similar manner as described in Example 9. Yield was 6 g (46%); ¹ H NMR (CDCl ₃ ) δ 1.79-1.94 (m, 1H), 2.00-2.17 (m, 1H), 2.42-2.53 (m, 2H), 2.78-2.88 (m, 2H), 7.17 (d, 2H) , 7.45 (d, 2 H).
[194] Example 11 (Departures)
[195] 1-(3,4-methylenedioxyphenyl) cyclobutanecarboxylic acid
[196] The title compound was prepared from 3,4-methylenedioxyphenylacetonitrile and 1,3-dibromopropane in a similar manner to the method described in Example 9.
[197] 2.1 equivalents of NaH and 1.1 equivalents of 1,3-dibromopropane were used.
[198] A mixture of 3,4-methylenedioxyphenylacetonitrile and 1,3-dibromopropane was added at 0 ° C. The resulting 1- (3,4-methylenedioxyphenyl) cyclobutaneacetonitrile was purified by silica gel chromatography using 94: 6 petroleum ether-EtOAc as eluent. The product (11 mmol) was refluxed for 7 hours with KOH (33 mmol) and H ₂ 0 (1.4 mL) in ethylene glycol (16.6 mL). The cooled mixture was extracted with Et ₂ 0. The aqueous layer was acidified and extracted with Et ₂ 0. The crude product was chromatographed on silica gel using 99: 1 EtOAc-HOAc as eluent to afford the desired product. Yield was 1.1 g (26%); ¹ H NMR (CDCl ₃ ) δ 1.80-1.95 (m, 1H), 1.97-2.12 (m, 1H), 2.40-2.50 (m, 2H), 2.75-2.85 (m, 2H), 5.91 (s, 2H) , 6.75-6.80 (m, 3H).
[199] Example 12 (Departures)
[200] 1-Phenyl-2-cis-methylcyclobutanecarboxylic acid
[201] The title compound was prepared from phenylacetonitrile and 1,3-dibromo-1-methylpropane in a similar manner as described in Example 9. Stir overnight to react with NaH. The obtained 1-phenyl-2-methylcyclobutaneacetonitrile was a mixture of cis isomers and trans isomers. The isomers were separated by chromatography on silica gel using 85:15 hexanes-toluene as eluent. The yield of 1-phenyl-2-cis-methylcyclobutanecarboxylic acid was 0.83 g (14%); ¹ H NMR (CDCl ₃ ) δ 1.32 (d, 3H), 1.87 (m, 1H), 2.05 (m, 1H), 2.22 (m, 1H), 2.86 (m, 1H), 3.04 (m, 1H), 7.20-7.40 (m, 5 H).
[202] Example 13 (Departures)
[203] 1-Phenyl-2-trans-methylcyclobutanecarboxylic acid
[204] In Example 12, the fraction containing the trans isomer obtained in the preparation of 1-phenyl-2-cis-methylcyclobutanecarboxylic acid was pooled to obtain 0.55 g of 1-phenyl-2-trans-methylcyclobutanecarboxylic acid; ¹ H NMR (CDCl ₃ ) δ 0.79 (d, 3H), 1.47 (m, 1H), 2.22 (m, 1H), 2.60 (m, 1H), 2.74 (m, 1H), 3.12 (m, 1H), 7.20-7.40 (m, 5 H).
[205] Example 14 (Departures)
[206] 1-(1-naphthyl) cyclobutanecarboxylic acid
[207] The title compound was prepared from 1-naphthylacetonitrile and 1,3-dibromopropane in a similar manner as described in Example 9. The reaction mixture with NaH was stirred overnight. 1-(1-naphthyl) cyclobutaneacetonitrile was refluxed with KOH overnight. The yield was 6.9 g (42%); ¹ H NMR (CDCl ₃ ) δ 1.92 (m, 1H), 2.25 (m, 1H), 2.73 (m, 2H), 3.05 (m, 2H), 7.47 (m, 4H), 7.80 (m, 3H).
[208] Example 15 (Departures)
[209] 1-(2-naphthyl) cyclobutanecarboxylic acid
[210] The title compound was prepared from 2-naphthylacetonitrile and 1,3-dibromopropane in a similar manner to that described in Example 9. Yield was 3.0 g (44%).
[211] Example 16 (Departure Material)
[212] 1- (3-methylphenyl) cyclobutanecarboxylic acid
[213] The title compound was prepared from 3-methylphenylacetonitrile and 1,3-dibromopropane in a similar manner to that described in Example 9. 0.72 g (54%) was obtained; ¹ H NMR (CDCl ₃ ) δ 1.75-1.92 (m, 1H), 1.98-2.16 (m, 1H), 2.28 (s, 3H), 2.42-2.59 (m, 2H), 2.75-2.90 (m, 2H) , 6.95-7.15 (m, 3H), 7.2 (d, 1H).
[214] Example 17 (Departures)
[215] 1-(2-methoxyphenyl) cyclobutanecarboxylic acid
[216] Similar to the method described in Example 9, the title compound was prepared from 2-methoxyphenylacetonitrile and 1,3-dibromopropane. 3.9 g (15%) were obtained; ¹ H NMR (CDCl ₃ ) δ 1.85 (m, 1H), 2.20 (m, 1H), 2.50 (m, 2H), 2.80 (m, 2H), 3.80 (m, 3H), 6.84 (d, 1H), 6.96 (t, 1 H), 7.22 (t, 2 H).
[217] Example 18 (Departures)
[218] 1-(4-methylphenyl) cyclobutanecarboxylic acid
[219] The title compound was prepared from 4-methylphenylacetonitrile and 1,3-dibromopropane using a method analogous to that described in Example 9. The crude product was washed with 90:10 petroleum ether-toluene. The yield was 82%; ¹ H NMR (CDCl ₃ ) δ 1.86 (m, 1H), 2.05 (m, 1H), 2.32 (s, 3H), 2.49 (m, 2H), 2.82 (m, 2H), 7.17 (m, 4H), 9.6 (br, 1 H).
[220] Example 19 (Departures)
[221] 1- (2-methylphenyl) cyclobutanecarboxylic acid
[222] The title compound was prepared from 2-methylphenylacetonitrile and 1,3-dibromopropane using a method analogous to that described in Example 9. The crude product was washed with 90:10 petroleum ether-toluene. The yield was 83%; ¹ H NMR (CDCl ₃ ) δ 1.85 (m, 1H), 2.21 (m, 4H), 2.55 (m, 2H), 2.84 (m, 2H), 7.07-7.23 (m, 4H), 11.0 (br, 1H).
[223] Example 20 (Departures)
[224] 1-(4-fluorophenyl) cyclobutanecarboxylic acid
[225] The title compound was prepared from 4-fluorophenylacetonitrile and 1,3-dibromopropane using a method analogous to that described in Example 9. The crude product was washed with 90:10 petroleum ether-toluene as eluent; ¹ H NMR (CDCl ₃ ) δ 1.86 (m, 1H), 2.06 (m, 1H), 2.47 (m, 2H), 2.83 (m, 2H), 7.00 (m, 2H), 7.26 (m, 2H), 11.1 (br, 1 H).
[226] Example 21 (Departures)
[227] 1- (2-fluorophenyl) cyclobutanecarboxylic acid
[228] The title compound was prepared from 2-fluorofluoroacetonitrile and 1,3-dibromopropane using a method similar to that described in Example 9. The crude product was chromatographed on silica gel using 90: 8: 2 petroleum ether-EtOAc-HOAc as eluent. The yield was 86%; ¹ H NMR (CDCl ₃ ) δ 1.88 (m, 1H), 2.24 (m, 1H), 2.53 (m, 2H), 2.84 (m, 2H), 6.95-7.28 (m, 4H), 11.8 (br, 1H ).
[229] Example 22 (Departures)
[230] 1- (3-fluorophenyl) cyclobutanecarboxylic acid
[231] The title compound was prepared from 3-fluorophenylacetonitrile and 1,3-dibromopropane in a similar manner as described in Example 9. The yield was 70%; ¹ H NMR (CDCl ₃ ) δ 1.89 (m, 1H), 2.06 (m, 1H), 2.49 (m, 2H), 2.83 (m, 2H), 6.98 (m, 3H), 7.23 (m, 1H), 10.2 (br, 1 H).
[232] Example 23 (Departures)
[233] 1-(3-methoxyphenyl) cyclobutanecarboxylic acid
[234] The title compound was prepared from 3-methoxyphenylacetonitrile and 1,3-dibromopropane in a similar manner to that described in Example 9. The crude product was washed with 85:15 petroleum ether-toluene. The yield was 70%; ¹ H NMR (CDCl ₃ ) δ 1.84 (m, 1H), 2.04 (m, 1H), 2.51 (m, 2H), 2.82 (m, 2H), 3.79 (s, 3H), 6.83 (m, 3H), 7.22 (m, 1 H), 10.9 (br, 1 H).
[235] Example 24 (Departures)
[236] 1-(4-methoxyphenyl) cyclobutanecarboxylic acid
[237] The title compound was prepared from 4-methoxyphenylacetonitrile and 1,3-dibromopropane in a similar manner to that described in Example 9. The yield was 83%; ¹ H NMR (CDCl ₃ ) δ 1.90 (m, 1H), 2.04 (m, 1H), 2.47 (m, 2H), 2.81 (m, 2H), 3.78 (s, 3H), 6.86 (m, 2H), 7.22 (m, 2 H), 10.8 (br, 1 H).
[238] Example 25 (Departure Material)
[239] 1-(2-thienyl) cyclobutanecarboxylic acid
[240] The title compound was prepared from 2-thienylacetonitrile and 1,3-dibromopropane in a similar manner to that described in Example 9. 1- (2-thienyl) cyclobutaneacetonitrile was chromatographed on silica gel using 98: 2 petroleum ether-EtOAc as eluent. The yield was 36%; ¹ H NMR (CDCl ₃ ) δ 2.18 (m, 1H), 2.28 (m, 1H), 2.60 (m, 2H), 2.83 (m, 2H), 6.97 (m, 1H), 7.09 (m, 1H), 7.26 (m, 1 H).
[241] Example 26 (Departures)
[242] 1-(3-thienyl) cyclobutanecarboxylic acid
[243] The title compound was prepared from 3-thienylacetonitrile and 1,3-dibromopropane in a similar manner to that described in Example 9. 1-(3-thienyl) cyclobutaneacetonitrile was chromatographed on silica gel using 96: 4 petroleum ether-EtOAc as eluent. The yield was 60%; ¹ H NMR (CDCl ₃ ) δ 2.11 (m, 1H), 2.34 (m, 1H), 2.58 (m, 2H), 2.79 (m, 2H), 7.14 (m, 1H), 7.26 (m, 1H), 7.36 (m, 1 H).
[244] Example 27 (Departures)
[245] 1-phenyl-3,3-diethylcyclobutanecarboxylic acid
[246] NaH (60% in mineral oil, dispersion, 107 mmol) was washed several times with n-pentane and suspended in DMF. A mixture of 1-phenylacetonitrile (42.7 mmol) and di-O-p-toluene-sulfonyl-2-diethyl-1,3-propanediol (42.7 mmool) in DMF was added dropwise. The reaction mixture was stirred at 70 ° C overnight. H ₂ O was carefully added to decompose excess hydride. Extraction with EtOAc and drying of the glass layer (MgSO ₄ ) followed by evaporation of the solvent gave 1-phenyl-3,3-diethylcyclobutaneacetonitrile (39.8 mmol), which was KOH in ethylene glycol (370 mL). (40%, 490 mL) was refluxed for 10 hours. The mixture was cooled to rt and washed with EtOAc. The mixture was cooled to rt and washed with EtOAc. The aqueous layer was acidified and extracted with EtOAc. The organic layer was dried (MgSO ₄ ) and then concentrated to afford the desired product. Treatment with MeOH: H ₂ 0 of 1: 1 then crystallization yielded an oil. Yield was 1.4 g (14%); ¹ H NMR (CDCl ₃ ) δ 0.65 (t, 3H), 0.77 (t, 3H), 1.28 (q, 2H), 1.49 (q, 2H), 2.29 (d, 2H), 2.69 (d, 2H), 7.20-7.35 (m, 5 H).
[247] Example 28 (Departure Material)
[248] 1-phenyl-3,3-trimethylenecyclobutanecarboxylic acid
[249] The title compound was prepared from 1-phenyl-acetonitrile and di-0-p-toluene-sulfonyl-2,2-trimethylene-1,3-propanediol in a similar manner to that described in Example 27. The resulting 1-phenyl-3,3-trimethyleneacetonitrile was chromatographed on silica gel using 98: 2 petroleum ether-EtOAc as eluent. The desired carboxylic acid yield was 32%; ¹ H NMR (CDCl ₃ ) δ 1.93 (m, 4H), 2.36 (m, 2H), 2.60 (m, 2H), 2.89 (m, 2H), 7.38 (m, 5H).
[250] Example 29 (Departures)
[251] 1-Phenyl-3,3-dimethylcyclobutanecarboxylic acid
[252] NaH (60% dispersion in mineral oil, 77.8 mmol) was washed several times with n-pentane and suspended in DMF. Phenylacetonitrile (31 mmol) in DMF was added followed by 3-bromo-0-p-toluenesulfonyl-2-dimethyl-1-propanol (31 mmol) in DMF. The reaction mixture was stirred at 75 ° C overnight. H ₂ O was carefully added to decompose excess hydride. Extraction with toluene and drying the organic layer (MgSO ₄ ) followed by evaporation of the solvent yielded 1-phenyl-3-dimethylcyclobutaneacetonitrile (31 mmol), which was KOH (128 mmol) in ethylene glycol (35 mL). With reflux for 2 hours. After cooling to room temperature, toluene and H ₂ O were added and the layers were separated. The aqueous layer was acidified and extracted with EtOAc. The organic layer was dried (MgSO ₄ ) and concentrated to afford the desired product. The yield was 6.3 g (99%); ¹ H NMR (CDCl ₃ ) δ 0.99 (s, 3H), 1.16 (s, 3H), 2.37 (d, 2H), 2.76 (d, 2H), 7.20-7.35 (m, 5H).
[253] Example 30 (Departures)
[254] 1-Phenyl-3-trans-methylcyclobutanecarboxylic acid
[255] The title compound was prepared in a similar manner as described in Example 29. NaH (60% dispersion in mineral oil, 77.8 mmol) was reacted with phenylacetonitrile and (R) -3-bromo-0-p-toluenesulfonyl-2-methyl-1-propanol at room temperature. (R)-3-bromo-0-p-toluenesulfonyl-2-methyl-1 -propanol with (R)-(-)-3-bromo-2-methyl-1 -propanol (33 mmol) p-toluenesulfonyl chloride (39 mmol) was prepared by reacting in pyridine for 17 hours. The 1-phenyl-3 methylcyclobutaneacetonitrile obtained contained 75% cis isomer and 25% trans isomer. To separate the two isomers, allyl esters of acids were prepared. 1-Phenyl-3-methylcyclobutanecarboxylic acid (24 mmol) was refluxed with pure SOCl ₂ (25 mL) for 1 h. SOCl ₂ was evaporated and the residue was taken up in toluene and allyl alcohol (26 mmol) and pyridine (26 mmol) was added. The mixture was stirred overnight to give allyl 1 -phenyl-3 -methylcyclobutanecarboxylate, which was chromatographed on silica gel containing 2% AgNO ₃ using a hexane gradient eluent with a ratio of hexane EtOAc of 95: 5. It was. 1.3 g of allyl 1 -phenyl-3 -trans -methylcyclobutanecarboxylate were obtained. The allyl ester was then hydrolyzed with KOH as above. The product obtained contained 10% cis isomer. Total yield was 0.66 g (11%); ¹ H NMR (CDCl ₃ ) δ 1.09 (d, 3H), 2.15-2.30 (m, 1H), 2.38-2.48 (m, 2H), 2.65-2.75 (m, 2H), 7.21-7.41 (m, 5H) .
[256] Example 31 (Departures)
[257] 1-Phenyl-3-cis-methylcyclobutanecarboxylic acid
[258] The fraction containing allyl 1-phenyl-3-cis-methylcyclobutane-carboxylate obtained in the preparation of 1-phenyl-3-trans-methylcyclobutanecarboxylic acid in Example 30 was pooled and petroleum ether-toluene Silica gel chromatography was performed using a petroleum ether gradient eluent having a ratio of 60:40. The allyl ester was hydrolyzed to give the desired product containing less than 2% trans isomers. Total yield was 0.18 g (1%); ¹ H NMR (CDCl ₃ ) δ 1.03 (d, 3H), 2.02-2.10 (m, 2H), 2.43-2.60 (m, 1H), 2.97-3.05 (m, 2H), 7.21-7.33 (m, 5H) .
[259] Example 32 (Departures)
[260] 1- (4-nitrophenyl) cyclobutanecarboxylic acid
[261] NaH (80% dispersion in mineral oil, 0.26 mol) was suspended in DMF under a nitrogen atmosphere. Methyl 4-nitrophenylcarboxylate (0.13 mol) prepared by refluxing MeOH (100 mL) and concentrated H ₂ SO ₄ (1 mL) with 4-nitrophenylacetic acid (0.2 mol) was dissolved in DMF. To this was added 1,3-dibromopropane (0.13 mol) in DMF. Stir at room temperature for 1.5 hours. H ₂ O was carefully added to decompose excess hydride. H ₂ 0 was further added and extracted with toluene. The organic layer was washed with H ₂ 0, dried (MgSO ₄ ) and then concentrated to afford methyl 1-(4-nitrophenyl) -cyclobutanecarboxylate which was stirred overnight with 0.5 M NaOH (128 mL) in TNF. . TNF was evaporated and the residue was dissolved in H ₂ 0 and extracted with EtOAc. The aqueous layer was acidified and extracted with EtOAc. The organic layer was dried (MgSO ₄ ) and concentrated to afford the desired product and washed with EtOH / H ₂ O. Yield was 0.7 g (12%); ¹ H NMR (CDCl ₃ ) δ 1.90 (m, 1H), 2.05-2.20 (m, 1H), 2.50-2.60 (m, 2H), 2.90 (m, 2H), 7.52 (d, 2H), 8.2 (d , 2H).
[262] Example 33 (Departures)
[263] 1-(3-nitrophenyl) cyclobutanecarboxylic acid
[264] The title compound was prepared from 3-nitrophenylcarboxylate and 1,3-dibromopropane in a similar manner as described in Example 32. 2.5 equivalents of NaH were used. Yield was 2.4 g (37%); ¹ H NMR (CDCl ₃ ) δ 1.95 (m, 1H), 1.10-1.25 (m, 1H), 2.50-2.65 (m, 2H), 2.95 (m, 2H), 7.50 (t, 1H), 7.60 (d , 1H), 8.10-8.20 (m, 2H).
[265] Example 34 (Departures)
[266] 1-Phenyl-3-methylenecyclobutanecarboxylic acid
[267] Methyltriphenylphosphonium bromide (41 mmol) was added to a suspension of KOtBu (41 mmol) in toluene (200 mL). After stirring for 45 min at 65 ° C., 1-cyano-1-phenyl-3-oxycyclobutane (34 mmol) was added. The reaction mixture was stirred for another 5 minutes. The mixture was cooled to room temperature and then washed twice with H ₂ O. The organic layer was dried (Na ₂ SO ₄ ) and evaporated. The residue was chromatographed on silica gel using 97: 3 petroleum ether-EtOAc as eluent; ¹ H NMR (CDCl ₃ ) δ 3.29 (m, 2H), 3.59 (m, 2H), 5.04 (m, 2H), 7.24-7.52 (m, 5H).
[268] The resulting product, 1-phenyl-3methylenecyclobutane-acetonitrile, was hydrolyzed in a similar manner as described in Example 9. The yield of the desired carboxylic acid was 3.1 g (48%).
[269] Example 35 (Departures)
[270] 1-(2,4-dinitrophenyl) cyclobutanecarboxylic acid
[271] 1-phenylcyclobutanecarboxylic acid (28.4 mmol) was added to fuming HNO ₃ (81 mL) and stirred for 1 hour while maintaining 0 ° C. The reaction mixture was poured on ice and the resulting crystals were filtered and washed with EtOH to yield 5.5 g (73%) of 1-(2,4-dinitrophenyl) -cyclobutanecarboxylic acid; ¹ H NMR (CDCl ₃ ) δ 1.83-1.96 (m, 1H), 2.38-2.48 (m, 3H), 2.90-3.00 (m, 2H), 7.70 (d, 1H), 8.47 (dd, 1H), 8.77 (d, 1H).
[272] Example 36
[273] 2- (diethylamino) ethyl 1-phenylcyclobutanecarboxylate hydrochloride
[274] 1-Phenylcyclobutanecarboxylic acid (1.9 mmol) was refluxed with SOCl ₂ (5 mL). After 0.5 h, the reaction mixture was evaporated and the residue dissolved in toluene. Diisopropylaminoethanol (3.8 mmol) was added and the mixture was heated to 80 ° C. for 1.5 h. The reaction mixture was filtered and subjected to silica gel chromatography using 95: 5 toluene-Et ₃ N as eluent. Yield was 1.3 g (73%); Melting point 137-139 ° C .; ¹ H NMR (D ₂ 0) δ 1.25 (t, 6H), 1.92-2.01 (m, 1H), 2.07-2.16 (m, 1H), 2.64 (m, 2H), 2.89 (m, 2H), 3.11 ( q, 4H), 3.50 (t, 2H), 4.48 (t, 2H), 7.44 (m, 1H), 7.48 (m, 2H), 7.53 (m, 2H). Anal (C ₁₇ H ₂₅ NO ₂ HCl) C, H, N.
[275] Example 37
[276] 3-(diethylamino) propyl 1-
[277] Phenylcyclobutanecarboxylate Hydrochloride
[278] The title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with 3-diethylaminopropanol at 80 ° C. for 5 hours in a similar manner as described in Example 36. The reaction mixture was filtered and subjected to silica gel chromatography using 95: 5 toluene-Et ₃ N as eluent. Yield was 0.8 g (45%); Melting point 108-111 ° C .; ¹ H NMR (D ₂ 0) δ 1.25 (t, 6H), 1.91-2.14 (m, 4H), 2.62 (m, 2H), 2.89 (m, 4H), 3.13 (q, 4H), 4.27 (t, 2H), 7.43 (m, 1H), 7.48 (m, 2H), 7.53 (m, 2H). Anal (C ₁₈ H ₂₇ NO ₂ HCl) C, H, N.
[279] Example 38
[280] 2- (diethylamino) ethyl 1-phenyl-3,3-
[281] Dimethylcyclobutanecarboxylate Hydrochloride
[282] In a similar manner to that described in Example 36, the title compound was prepared from the compound prepared in Example 29 and 2-diethylaminoethanol. The crude product was subjected to silica gel chromatography using 90:10 toluene-Et ₃ N as eluent. The yield was 0.18 g (44%); Melting point 185-186 deg. ¹ H NMR (CD ₃ OD) δ 1.0 (s, 3H), 1.13 -1.20 (m, 9H), 2.42 (d, 2H), 2.75 (d, 2H), 2.98 (q, 4H), 3.35 (m, 2H), 4.36 (m, 2H), 7.21-7.39 (m, 5H). Assay (C ₁₉ H ₂₉ NO ₂ .HCl.0.5H ₂ 0) C, N; H: theoretical value, 9.0; Analyzes, 8. 4.
[283] Example 39
[284] 2- (diethylamino) ethyl 1-phenyl-3,3-
[285] Diethylcyclobutanecarboxylate hydrochloride
[286] In a similar manner to that described in Example 36, the title compound was prepared from the compound prepared in Example 27 and 2-diethylaminoethanol. The crude product was chromatographed on silica gel using 90:10 toluene-Et ₃ N as eluent. Yield was 0.26 g (47%); Melting point 152-154 ° C .; ¹ H NMR (CD ₃ OD) δ 0.69 (t, 3H), 0.80 (t, 3H), 1.15 (t, 6H), 1.31 (q, 2H), 1.50 (q, 2H), 2.35 (d, 2H) , 2.70 (d, 2H), 2.98 (q, 4H), 3.35 (m, 2H), 4.35 (m, 2H), 7.20-7.40 (m, 5H). Analysis _{(C 21 H 33 NO 2 ·} HCl) C, H, N.
[287] Example 40
[288] 2-(diisopropylamino) ethyl 1-
[289] Phenylcyclobutanecarboxylate Hydrochloride
[290] The title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride and 2-diisopropylaminoethanol at 80 ° C. for 17 hours in a similar manner as described in Example 36. The undissolved oil was separated from the reaction mixture, and then the toluene solution was chromatographed on silica gel using 98: 2 toluene-Et ₃ N as eluent. Yield was 1.5 g (77%); Melting point 110-114 ° C; ¹ H NMR (D ₂ O) δ 1.33 (d, 12H), 1.97 (m, 1H), 2.11 (m, 1H), 2.63 (m, 2H), 2.89 (m, 2H), 3.47 (t, 2H) , 3.70 (m, 2H), 4.46 (t, 2H), 7.44 (m, 1H), 7.48 (m, 2H), 7.53 (m, 2H). Analysis _{(C 19 H 29 NO 2 ·} HCl) C, H, N.
[291] Example 41
[292] 2-(diisopropylamino) ethyl 1-phenyl-2-
[293] Cis-methylcyclobutanecarboxylate hydrochloride
[294] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 12 and 2-diisopropylaminoethanol. The crude product was chromatographed on silica gel using 90:10 toluene-EtOAc as eluent. The yield was 0.16 g (32%); Melting point 64-66 ° C; ¹ H NMR (CD ₃ OD) δ 1.15-1.25 (br, 12H), 1.27 (d, 3H), 1.81 (m, 1H), 2.08 (m, 1H), 2.18 (m, 1H), 2.93 (m, 1H), 3.09 (m, 1H), 3.35 (m, 2H), 3.49 (br, 1H), 3.57 (br, 1H), 4.33 (m, 1H), 4.52 (m, 1H), 7.24 (m, 3H ), 7.34 (m, 2 H).
[295] Example 42
[296] 2-(diisopropylamino) ethyl 1-phenyl-2-
[297] Trans-methylcyclobutanecarboxylate hydrochloride
[298] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 13 and 2-diisopropylaminoethanol. The crude product was chromatographed on silica gel using 90:10 toluene-EtOAc as eluent. The yield was 0.30 g (60%); Melting point 108-112 ° C .; ¹ H NMR (CD ₃ 0D) δ 0.72 (d, 3H), 1.25 (d, 12H), 1.50 (m, 1H), 2.19 (m, 1H), 2.56 (m, 1H), 2.80 (m, 1H) , 3.20 (q, 1H), 3.32-3.45 (m, 2H), 3.60 (m, 2H), 4.41 (m, 2H), 7.27 (m, 3H), 7.37 (m, 2H). Anal (C ₂₀ H ₃₁ NO ₂ HCl) C, H, N.
[299] Example 43
[300] 2-(diisopropylamino) ethyl 1 -phenyl -3-
[301] Cis-methylcyclobutanecarboxylate hydrochloride
[302] In a similar manner as described in Example 36, the title compound was prepared from the compound prepared in Example 31. The crude product was chromatographed using 90:10 hexanes-Et ₃ N as eluent. Yield was 0.9 g (73%). Melting point 155-156 deg. ¹ H NMR (CD ₃ OD) δ 1.09 (d, 3H), 1.25 (d, 12H), 2.18-2.35 (m, 1H), 2.40-2.48 (m, 2H), 2.67-2.75 (m, 2H), 3.36 (t, 2H), 3.60 (t, 2H), 4.32 (t, 2H), 7.20-7.44 (m, 5H). Anal (C ₂₀ H ₃₁ N0 ₂ · HCl) C, H, N.
[303] Example 44
[304] 2-(diisopropylamino) ethyl 1 -phenyl -3-
[305] Trans-methylcyclobutanecarboxylate hydrochloride
[306] In a similar manner as described in Example 36, the title compound was prepared from the compound prepared in Example 30. The crude product was chromatographed on silica gel using 90:10 hexanes-Et ₃ N as eluent. Yield was 0.14 g (49%); Melting point 132-135 ° C; ¹ H NMR (CD ₃ OD) δ 1.05 (d, 3H), 1.33 (d, 6H), 1.38 (d, 6H), 2.06-2.11 (m, 2H), 2.5 (m, 1H), 2.99-3.08 ( m, 4H), 3.5 (m, 2H), 4.7 (t, 2H), 7.19-7.23 (m, 2H), 7.29-7.32 (m, 2H). Anal (C ₂₀ H ₃₁ NO ₂ HCl) C, H, N.
[307] Example 45
[308] 2- (diisopropylamino) ethyl 1-phenyl-
[309] 3,3-dimethylcyclobutanecarboxylate hydrochloride
[310] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 29 and 2-diisopropylaminoethanol. The crude product was chromatographed using 90:10 toluene-EtOAc as eluent. The yield was 0.6 g (17%); Melting point 129-130 ° C .; ¹ H NMR (CD ₃ OD) δ 0.99 (s, 3H), 1.16 (s, 3H), 1.25 (d, 12H), 2.42 (d, 2H), 2.79 (d, 2H), 3.36 (t, 2H) , 3.61 (m, 2H), 4.35 (t, 2H), 7.20-7.40 (m, 5H). Analysis _{(C 21 H 33 NO 2 ·} HCl) C, H, N.
[311] Example 46
[312] 2- (diisopropylamino) ethyl 1-phenyl-
[313] 3,3-diethylcyclobutanecarboxylate hydrochloride
[314] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 27 and 2-diisopropylaminoethanol. The crude product was obtained using 90:10 of hexane-Et ₃ N as eluent. 0.38 g (45%) of a colorless oil were obtained; ¹ H NMR (CD ₃ OD) δ 0.70 (t, 3H), 0.80 (t, 3H), 1.22-1.38 (m, 14H), 1.50 (q, 2H), 2.35 (d, 2H), 2.70 (d, 2H), 3.35 (t, 2H), 3.60 (m, 2H), 4.35 (t, 2H), 7.20-7.40 (m, 5H). Anal (C ₂₃ H ₃₇ NO ₂ · HCl) C, H, N.
[315] Example 47
[316] 2- (diisopropylamino) ethyl 1-phenyl-
[317] 3,3-trimethylenecyclobutanecarboxylate fumaric acid
[318] By the method described in Example 36, the title compound was prepared from the compound prepared in Example 28 and 2-diisopropylaminoethanol. The crude product was chromatographed on silica gel using 92: 8 toluene-Et ₃ N as eluent. Fumaric acid (1 equiv) was added to pure amine. 0.75 g (35%) of crystallized product was obtained by evaporating the mixture and drying the oil for 2 days under vacuum (1 mmHg) P ₂ O ₅ ; Melting point 126-129 deg. ¹ H NMR (CDCl ₃ ) δ 1.21 (d, 12H), 1.83 (m, 4H), 2.05 (m, 2H), 2.52 (d, 2H), 2.90 (d, 2H), 3.06 (m, 2H), 3.45 (m, 2H), 4.40 (m, 2H), 6.75 (s, 2H), 7.27 (m, 5H). Analysis _{(C 22 H 33 N0 2 ·} C 4 H 4 O 4 · 0.5H 2 0) C, H, N.
[319] Example 48
[320] 2- (diisopropylamino) ethyl 1-phenyl-
[321] 3-methylenecyclobutanecarboxylate hydrochloride
[322] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 34 and 2-diisopropylaminoethanol. The crude product was chromatographed on silica gel using 97: 3 toluene-Et ₃ N as eluent. The yield was 0.62 g (55%); Melting point 163-164 캜; ¹ H NMR (CDCl ₃ ) δ 1.36 (m, 12H), 3.19 (m, 4H), 3.53 (m, 4H), 4.70 (t, 2H), 4.87 (m, 2H), 7.32 (m, 5H), 11.7 (br, 1 H). Analysis _{(C 20 H 29 NO 2 ·} HCl) C, H, N.
[323] Example 49
[324] 2-(diisopropylamino) ethyl 1-
[325] (3-nitrophenyl) cyclobutanecarboxylate hydrochloride
[326] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 33 and 2-diisopropylaminoethanol. The crude product was chromatographed on silica gel using 90:10 toluene-EtOAc as eluent. Yield was 0.5 g (29%); Melting point 124-129 deg. ¹ H NMR (CD ₃ OD) δ 1.35 (d, 12H), 1.83-2.02 (m, 1H), 2.08-2.25 (m, 1H), 2.55-2.65 (m, 2H), 2.90-3.0 (m, 2H ), 3.41 (t, 2H), 3.65 (m, 2H), 4.39 (t, 2H), 7.58-7.74 (m, 2H), 8.15 (m, 2H). Analysis _{(C 19 H 28 N 2 O} 4 · HCl) C, H, N.
[327] Example 50
[328] 2-(diisopropylamino) ethyl 1-
[329] (4-Nitrophenyl) cyclobutanecarboxylate hydrochloride
[330] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 32 and 2-diisopropylaminoethanol. The crude product was chromatographed twice on silica gel using 90:10 hexanes-Et ₃ N and 90:10 toluene-EtOAc as eluent. Yield was 0.26 g (51%); Melting point 145-146 캜; ¹ H NMR (CD ₃ OD) δ 1.29 (d, 12H), 1.90-1.98 (m, 1H), 2.21-2.30 (m, 1H), 2.57-2.63 (m, 2H), 2.92-2.98 (m, 2H ), 3.40 (t, 2H), 3.65 (m, 2H), 4.40 (t, 2H), 7.55-7.58 (m, 2H), 8.22-8.24 (m, 2H). Analysis _{(C 19 H 28 N 2 O} 4 · HCl) C, H, N.
[331] Example 51
[332] 2-(diisopropylamino) ethyl 1-
[333] (2,4-Dinitrophenyl) cyclobutanecarboxylate hydrochloride
[334] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 35 and 2-diisopropylaminoethanol. The crude product was chromatographed on silica gel using 90:10 toluene-EtOAc as eluent. Yield was 0.15 g (39%); Melting point 134-136 deg. ¹ H NMR (CD ₃ OD) δ 1.27 (d, 12H), 1.88-1.97 (m, 1H), 2.32-2.42 (m, 1H), 2.55-2.62 (m, 2H), 2.83-2.88 (m, 2H ), 3.37 (t, 2H), 3.67 (m, 2H), 4.47 (t, 2H), 7.90 (d, 1H), 8.55 (dd, 1H), 8.76 (d, 1H). Anal (C ₁₉ H ₂₇ N ₃ O ₆ HCl) C, H, N.
[335] Example 52
[336] 2-(diisopropylamino) ethyl 1-
[337] (3,4-Methylenedioxyphenyl) cyclobutanecarboxylate hydrochloride
[338] In the same manner as described in Example 36, the title compound was prepared from the compound prepared in Example 11 and 2-diisopropylaminoethanol. The amine salt was recrystallized from acetone-ether. The yield was 0.16 g (32%); Melting point 166-167 캜; ¹ H NMR (CD ₃ OD) δ 1.30 (d, 12H), 1.91 (m, 1H), 2.04 (m, 1H), 2.48 (m, 2H), 2.82 (m, 2H), 3.39 (t, 2H) , 3.65 (m, 2H), 4.39 (t, 2H), 5.93 (s, 2H), 6.81 (s, 3H). Analysis _{(C 20 H 29 NO 4 ·} HCl) C, H, N.
[339] Example 53
[340] 2-(diisopropylamino) ethyl 1-
[341] (2,3-Benzophenyl) cyclobutanecarboxylate hydrochloride
[342] In the same manner as described in Example 36, the title compound was prepared from the compound prepared in Example 14 and 2-diisopropylaminoethanol. Recrystallization of HCl-salt twice from acetone gave 2.85 g (34%); Melting point 199-201 deg. ¹ H NMR (CD ₃ OD) δ 1.00 (m, 12H), 1.98 (m, 1H), 2.28 (m, 1H), 2.75 (m, 2H), 3.08 (m, 2H), 3.28 (m, 4H) , 4.32 (t, 2 H), 7.40-8.00 (m, 7 H). Analysis _{(C 23 H 31 NO 2 ·} HCl) C, H, N.
[343] Example 54
[344] 2-(diisopropylamino) ethyl 1-
[345] (3,4-Benzophenyl) cyclobutanecarboxylate hydrochloride
[346] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 15 and 2-diisopropylaminoethanol. Yield was 1.98 g (73%); Melting point 129-132 캜; ¹ H NMR (CD ₃ OD) δ 1.11 (d, 12H), 1.95 (m, 1H), 2.11 (m, 1H), 2.67 (m, 2H), 2.94 (m, 2H), 3.33 (t, 2H) , 3.47 (m, 2H), 4.38 (t, 2H), 7.38 (d, 1H), 7.50 (m, 2H), 7.84 (m, 4H). analysis. (C ₂₃ H ₃₁ NO ₂ HCl) C, H, N.
[347] Example 55
[348] 2- (diisopropylamino) ethyl 1-
[349] (3-thienyl) cyclobutanecarboxylate hydrochloride
[350] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 26. The crude product was chromatographed on silica gel using toluene-Et ₃ N of 98: 2. 0.28 g (18%) was obtained; Melting point 125-126 DEG C; ¹ H NMR (CDCl ₃ ) δ 1.40 (m, 12H), 1.95 (m, 2H), 2.43 (m, 2H), 2.81 (m, 2H), 3.10 (m, 2H), 3.56 (m, 2H), 4.72 (m, 2H), 7.02 (dd, 1H), 7.15 (dd, 1H), 7.29 (dd, 1H). analysis. (C ₁₇ H ₂₇ NO ₂ S.HCl) C, H, N.
[351] Example 56
[352] 2-(1-pyrrolidino) ethyl 1-
[353] Phenylcyclobutanecarboxylate Hydrochloride
[354] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with 1- (2-hydroxyethyl) pyrrolidine at 80 ° C. for 21 hours. 0.9 g (50%) was obtained; Melting point 150-153 deg. ¹ H NMR (DMSO-d ₆ , 1% TFA) δ 1.73-1.90 (m, 5H), 1.98 (m, 1H), 2.47 (m, 2H), 2.72-2.82 (m, 4H), 3.26 (m, 2H), 3.37 (m, 2H), 4.35 (t, 2H), 7.24 (t, 1H), 7.30 (d, 2H), 7.35 (t, 2H). Anal (C ₁₇ H ₂₃ NO ₂ · HCl) C, H, N.
[355] Example 57
[356] (1-methyl-2-piperidino) methyl 1-
[357] Phenylcyclobutanecarboxylate Hydrochloride
[358] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride and 1-methyl-2-piperidinmethanol at 80 ° C. for 17 hours. Yield was 1.1 g (61%); Melting point 159-162 deg. ¹ H NMR (DMSO-d ₆ , 1% TFA) δ 1.42 (m, 1H), 1.54 (m, 1H), 1.60-1.87 (m, 5H), 1.97 (m, 1H), 2.42-2.55 (m, 5H), 2.81 (m, 2H), 2.95 (m, 0.8H), 3.11 (m, 0.4H), 3.21-3.35 (m, 1.6H), 3.53 (m, 0.2H), 4.21-4.39 (m, 2H), 7.26 (m, 1 H), 7.31-7.38 (m, 4H). Assay (C ₁₈ H ₂₅ NO ₂ .HCl) H, N; C: theory, 66.8; Anal. 67.5. The compound is present in two forms in DMSO-TFA solution.
[359] Example 58
[360] (1-Methyl-3-piperidino) methyl 1-
[361] Phenylcyclobutanecarboxylate Hydrochloride
[362] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride and 1-methyl-3-piperidinmethanol at 80 ° C. for 18 hours. 1. 4 g (77%) were obtained; Melting point 126-128 ° C; ¹ H NMR (D ₂ O) δ 1.15 (m, 1H), 1.67-1.81 (m, 2H), 1.97 (m, 2H), 2.05-2.19 (m, 2H), 2.42 (t, 1H), 2.64 ( m, 2H), 2.73 (m, 1H), 2.80 (s, 3H), 2.87 (m, 2H), 3.17 (d, 1H), 3.49 (d, 1H), 4.09 (q, 1H), 4.17 (q , 1H), 7.44 (t, 1H), 7.49 (d, 2H), 7.54 (t, 2H). Analysis _{(C 18 H 25 NO 2 ·} HCl) C, H, N.
[363] Example 59
[364] (1-Methyl-3-piperidino) methyl 1-
[365] Phenyl 3,3-dimethylcyclobutanecarboxylate hydrochloride
[366] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 29 and 1 -methyl-3 -piperidinemethanol. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. Yield was 0.54 g (42%); Melting point 155-157 캜; ¹ H NMR (CD ₃ OD) δ 1.0-1.15 (m, 7H), 1.62-1.90 (m, 3H), 2.03 (br, 1H), 2.3-2.41 (m, 3H), 2.6-2.8 (m, 6H ), 3.0 (brd, 1 H), 3.3-(C ₂₀ H ₂₉ NO ₂ .HCl.0.4H ₂ 0) C, H, N.
[367] Example 60
[368] 1-methyl-4-piperidinyl-1-
[369] Phenylcyclobutanecarboxylate Hydrochloride
[370] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride and 1-methyl-4-hydroxypiperidine at 80 ° C. for 20 hours. Yield was 0.77 g (44%); Melting point 203-206 캜; ¹ H NMR (DMSO-d ₆ , 1% TFA) δ 1.76 (d, 2H), 1.83 (m, 1H), 1.96 (m, 2H), 2.05 (t, 1H), 2.41-2.51 (m, 2H) , 2.53-2.85 (m, 6H), 3.03 (q, 1H), 3.20 (d, 1H), 3.34 (d, 1H), 4.8 (m, 0.4H), 4.93 (m, 0.6H), 7.23-7.40 (m, 5 H). Assay (C ₁₇ H ₂₃ NO ₂ · HCl) C, H, N. The compound is present in two forms in DMSO-TFA solution.
[371] Example 61
[372] 1-Methyl-4-piperidinyl 1-phenyl-
[373] 3,3-dimethylcyclobutanecarboxylate hydrochloride
[374] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 29 and 1 -methyl-4 -hydroxypiperidine. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. Yield was 0.56 g (45%); Melting point 204-205 캜; ¹ H NMR (DMSO-d ₆ ) δ 0.98 (s, 3H), 1.11 (s, 3H), 1.73 (br, 2H), 1.97 (br, 2H), 2.30-2.35 (m, 2H), 2.63 (s , 3H), 2.66-2.71 (m, 2H), 3.09 (br, 2H), 3.35 (br, 2H), 4.83 (br, 1H), 7.22-7.39 (m, 5H). Analysis _{(C 19 H 27 NO 2 ·} HCl) C, H, N.
[375] Example 62
[376] 1-methyl-3-pyrrolidinyl 1-
[377] Phenylcyclobutanecarboxylate Hydrochloride
[378] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride and 1-methyl-3 hydroxypyrrolidine at 80 ° C. for 17 hours. Yield was 1.1 g (67%); Melting point 153-155 캜; ¹ H NMR (DMSO-d ₆ , 1% TFA) δ 1.83 (m, 1.5H), 1.96 (m, 1.5H), 2.17 (m, 0.5H), 2.38-2.51 (m, 2.5H), 2.64 ( t, 1.5H), 2.73-2.92 (m, 4H), 2.97 (m, 0.5H), 3.06 (m, 0.5H), 3.32 (m, 0.5H), 3.54 (m, 1.5H), 3.76 (m , 0.5H), 5.26 (m, 1H), 7.23-7.39 (m, 5H). Analysis _{(C 16 H 21 NO 2 ·} HCl) C, H, N.
[379] Example 63
[380] 3-Tropanyl 1-phenylcyclobutanecarboxylate hydrochloride
[381] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with tropin at 80 ° C. for 22 hours. Yield was 0.5 g (28%); Melting point 181-183 ° C .; ¹ H NMR (D ₂ O) δ 1.78 (q, 2H), 1.96 (m, 1H), 2.04 (d, 2H), 2.13 (m, 3H), 2.38 (m, 2H), 2.64 (m, 2H) , 2.77 (s, 3H), 2.87 (m, 2H), 3.82 (m, 2H), 5.07 (t, 1H), 7.42 (m, 1H), 7.47 (m, 2H), 7.52 (m, 2H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[382] Example 64
[383] 3-quinucridinyl 1-phenylcyclobutanecarboxylate hydrochloride
[384] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with 3-quinucridinol at 80 ° C. for 15 hours. Yield was 0.4 g (22%); Melting point 163-168 deg. ¹ H NMR (D ₂ O) δ 1.80 (m, 2H), 1.88-2.02 (m, 2H), 2.04-2.17 (m, 2H), 2.38 (m, 1H), 2.59-2.70 (m, 2H), 2.90 (m, 2H), 3.08 (q, 1H), 3.18 (d, 1H), 3.28-3.39 (m, 3H), 3.69 (m, 1H), 5.18 (m, 1H), 7.42 (m, 1H) , 7.47-7.54 (m, 4H). Anal (C ₁₈ H ₂₃ NO ₂ HCl0.5H ₂ 0) C, H, N.
[385] Example 65
[386] 3-(R)-Quinukridinyl 1-
[387] Phenylcyclobutanecarboxylate Hydrochloride
[388] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with R (-)-3-quinucridinol at 80 ° C. for 30 hours. The yield was 0.43 g (31%); Melting point 219-223 deg. ¹ H NMR (D ₂ O) δ 1.80 (m, 2H), 1.88-2.02 (m, 2H), 2.04-2.17 (m, 2H), 2.38 (m, 1H), 2.59-2.70 (m, 2H), 2.90 (m, 2H), 3.08 (q, 1H), 3.18 (d, 1H), 3.28-3.39 (m, 3H), 3.69 (m, 1H), 5.18 (m, 1H), 7.42 (m, 1H) , 7.47-7.54 (m, 4H). Analysis _{(C 18 H 23 NO 2 ·} HCl) C, H, N.
[389] Example 66
[390] 3-quinucridinyl 1-phenyl-3,3-
[391] Dimethylcyclobutanecarboxylate Hydrochloride
[392] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 29 and 3-quinucridinol. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. Yield was 0.4 g (18%); Melting point 215-218 deg. ¹ H NMR (CD ₃ OD) δ 1.01 (s, 3H), 1.16 (s, 3H), 1.62-1.70 (m, 2H), 1.80-2.05 (m, 2H), 2.22 (br, 1H), 2.42 ( m, 2H), 2.75-2.98 (m, 4H), 3.22 (m, 3H), 3.60-3.70 (m, 1H), 5.0 (m, 1H), 7.2-7.38 (m, 5H). Anal (C ₂₀ H ₂₇ NOHCl) C, H, N.
[393] Example 67
[394] 3- (R) -quinucridinyl 1-phenyl-
[395] 3-dimethylcyclobutanecarboxylate hydrochloride
[396] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 21 and R (-)-3 quinucridinol. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. Yield was 0.19 g (45%); Melting point 212-214 캜; ¹ H NMR (CD ₃ OD) δ 1.03 (s, 3H), 1.18 (s, 3H), 1.65-2.05 (m, 4H), 2.23 (br, 1H), 2.44 (m, 2H), 2.75-3.00 ( m, 4H), 3.23 (m, 3H), 3.60-3.70 (m, 1H), 5.02 (m, 1H), 7.02-7.37 (m, 5H). Analysis _{(C 20 H 27 NO 2 ·} HCl) C, H, N.
[397] Example 68
[398] 3-quinucridinyl 1- (2-methylphenyl)
[399] Cyclobutanecarboxylate hydrochloride
[400] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 19 and 3-quinucridinol. The crude product was chromatographed on silica gel using 94: 6 toluene-Et ₃ N as eluent. Yield was 0.19 g (8%); Melting point 186-190 deg. ¹ H NMR (CDCl ₃ ) δ 1.32 (m, 1H), 1.49 (m, 1H), 1.92 (m, 3H), 2.10-2.38 (m, 5H), 2.49-3.17 (m, 6H), 3.22 (m , 3H), 3.54 (m, 1H), 5.07 (m, 1H), 7.17 (m, 4H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[401] Example 69
[402] 3-quinquinridinyl 1- (3-methylphenyl)
[403] Cyclobutanecarboxylate hydrochloride
[404] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 16 and 3-quinucridinol. 1- (3-Methylphenyl) cyclobutanecarbonyl chloride was reacted with 3-quinucridinol for 15 minutes at room temperature. Eluent was evaporated and the residue was partitioned between Et ₂ O and NaOH. The organic layer was extracted with 3 M HCl and basified, followed by extraction with Et ₂ O. The product was crystallized by addition of HCl (g) / Et ₂ 0 to give 0.25 g (53%); Melting point 196.5-198 ° C .; ¹ H NMR (CDCl ₃ ) δ 1.51 (m, 2H), 1.76-2.20 (m, 5H), 2.32 (s, 3H), 2.51 (m, 2H), 2.70-2.80 (m, 3H), 3.03 (d , 1H), 3.24 (m, 3H), 3.52 (m, 1H), 5.00 (m, 1H), 7.05-7.30 (m, 4H), 12.31 (bs, 1H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N, Cl.
[405] Example 70
[406] 3-quinucridinyl 1- (4-methylphenyl)
[407] Cyclobutanecarboxylate hydrochloride
[408] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 18 and 3-quinucridinol. The yield was 0.45 g (23%); Melting point 209-211 캜; ¹ H NMR (CDCl ₃ ) δ 1.57 (m, 2H), 1.88 (m, 4H), 2.33 (s, 3H), 2.55 (m, 2H), 2.83 (m, 5H), 3.23 (m, 3H) , 3.55 (ddd, 1 H), 5.02 (br, 1 H), 7.14 (s, 4 H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[409] Example 71
[410] 3-quinucridinyl 1- (2-methoxyphenyl)
[411] Cyclobutanecarboxylate hydrochloride
[412] The title compound was prepared in a similar manner as described in Example 36. 1- (2-methoxyphenyl) cyclobutane-carbonyl chloride prepared from the compound prepared in Example 17 was reacted with 3-quinucridinol at 80 ° C. for 25 hours. The crude product was obtained and chromatographed again on reversed phase PEP RPC HR 30/26 column using CH ₃ CN with 0.1% TFA at 25-50% gradient. Yield was 0.2 g (6%); Melting point 121-123 deg. ¹ H NMR (D ₂ O) δ 1.70-1.85 (m, 2H), 1.93-2.03 (m, 2H), 2.10 (m, 1H), 2.19 (m, 1H), 2.39 (m, 1H), 2.54 ( m, 2H), 2.77 (m, 2H), 3.01 (q, 1H), 3.18 (d, 1H), 3.28-3.37 (m, 3H), 3.75 (m, 1H), 3.85 (s, 3H), 5.24 (m, 1H), 7.13 (d, 1H), 7.17 (t, 1H), 7.45 (t, 1H), 7.53 (d, 1H). Analysis _{(C 19 H 25 NO 2 ·} HCl · H 2 0) C, H, N.
[413] Example 72
[414] 3-quinquinridinyl 1- (3-methoxyphenyl)
[415] Cyclobutanecarboxylate hydrochloride
[416] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 23 and 3-quinucridinol. The crude product was subjected to silica gel chromatography using CHCl ₃ -MeOH-conc. Ammonia with 98: 2: 0.2 as eluent. 0.42 g (5%) of absorbent crystals were obtained; Melting point 151-153 deg. ¹ H NMR (CDCl ₃ ) δ 1.59 (m, 2H), 1.92 (m, 4H), 2.31 (m, 1H), 2.53 (m, 2H), 2.88 (m, 4H), 3.22 (m, 3H), 3.56 (m, 1 H), 3.80 (s, 3 H), 5.02 (m, 1 H), 6.80 (m, 3 H), 7.21 (m, 1 H). Analysis _{(C 19 H 25 NO 3 ·} HCl) C, H, N.
[417] Example 73
[418] 3-quinucridinyl 1- (4-methoxyphenyl)
[419] Cyclobutanecarboxylate hydrochloride
[420] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 24 and 3-quinucridinol. The crude product was chromatographed on silica gel using CHCl ₃ -MeOH-conc. Ammonia 98: 2: 0.2 as eluent. Yield was 0.16 g (9%); Melting point 173-179 캜; ¹ H NMR (CDCl ₃ ) δ 1.59 (m, 2H), 1.92 (m, 4H), 2.32 (m, 1H), 2.51 (m, 2H), 2.90 (m, 4H), 3.20 (m, 3H), 3.52 (m, 1H), 3.80 (s, 3H), 5.01 (m, 1H), 7.83 (d, 2H), 7.17 (d, 2H). Analysis _{(C 19 H 25 NO 3 ·} HCl) C, H, N.
[421] Example 74
[422] 3-quinquinridinyl 1- (2-fluorophenyl)
[423] Cyclobutanecarboxylate hydrochloride
[424] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 21 and 3-quinucridinol. The crude product was chromatographed on silica gel using 94: 6 toluene-Et ₃ N as eluent. Yield was 0.42 g (18%); Melting point 155-157 캜; ¹ H NMR (CDCl ₃ ) δ 1.20-3.33 (m, 16H), 3.58 (m, 1H), 5.09 (m, 1H), 6.99-7.31 (m, 4H). Anal (C ₁₈ H ₂₂ FNO ₂ · HCl) C, H, N.
[425] Example 75
[426] 3-quinquinridinyl 1- (3-fluorophenyl)
[427] Cyclobutanecarboxylate hydrochloride
[428] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 22 and 3-quinucridinol. The crude product was chromatographed on silica gel using 94: 6 toluene-Et ₃ N as eluent. Yield was 0.54 g (25%); Melting point 179-184 deg. ¹ H NMR (CDCl ₃ ) δ 1.61 (m, 2H), 1.99 (m, 4H), 2.36 (m, 1H), 2.53 (m, 2H), 2.93 (m, 4H), 3.24 (m, 3H), 3.58 (m, 1 H), 5.04 (m, 1 H), 6.98 (m, 3 H), 7.37 (m, 1 H). Anal (C ₁₈ H ₂₂ FNO ₂ · HCl) C, H, N.
[429] Example 76
[430] 3-quinquinridinyl 1- (4-fluorophenyl)
[431] Cyclobutanecarboxylate hydrochloride
[432] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 20 and 3-quinucridinol. The crude product was chromatographed on silica gel using 94: 6 toluene-Et ₃ N as eluent. The yield was 0.65 g (31%); Melting point 189-192 캜; ¹ H NMR (CDCl ₃ ) δ 1.59 (m, 2H), 1.97 (m, 4H), 2.13 (m, 2H), 2.52 (m, 2H), 2.93 (m, 4H), 3.25 (m, 2H), 3.63 (m, 1H), 5.03 (m, 1H), 7.04 (m, 2H), 7.22 (m, 2H). analysis. (C ₁₈ H ₂₂ FNO ₂ HCl) C, H, N.
[433] Example 77
[434] 3-quinquinridinyl 1- (4-chlorophenyl)
[435] Cyclobutanecarboxylate hydrochloride
[436] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1- (4-chlorophenyl) -cyclobutanecarbonyl chloride with 3-quinucridinol at 80 ° C. for 25 hours. Yield was 0.7 g (43%); Melting point 205-208 캜; ¹ H NMR (D ₂ 0) δ 1.73-1.85 (m, 2H), 1.86-1.97 (m, 2H), 2.04-2.15 (m, 2H), 2.32 (m, 1H), 2.48-2.63 (m, 2H ), 2.87 (m, 2H), 3.12 (m, 1H), 3.22 (d, 1H), 3.27-3.42 (m, 3H), 3.73 (m, 1H), 5.17 (m, 1H), 7.37 (d, 2H), 7.43 (d, 2H). Anal (C ₁₈ H ₂₂ ClNO ₂ · HCl) C, H, N.
[437] Example 78
[438] 3-quinquinridinyl 1- (2-bromophenyl)
[439] Cyclobutanecarboxylate hydrochloride
[440] The title compound was prepared in a similar manner to that described in Example 36. 1- (2-bromophenyl) cyclobutanecarbonyl chloride prepared from the compound prepared in Example 9 was reacted with 3-quinucridinol at 75 ° C. overnight. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. Yield was 0.2 g (6%). Melting point 194-200 ° C; ¹ H NMR (CD ₃ OD) δ 1.47-1.74 (m, 2H), 1.82-2.50 (m, 3H), 2.18-2.35 (m, 2H), 2.54-2.71 (m, 2H), 2.79-2.97 (m , 3H), 3.11-3.27 (m, 4H), 3.67-3.75 (m, 1H), 5.10 (m, 1H), 7.16-7.22 (m, 1H), 7.37-7.49 (m, 2H), 7.57 (dd , 1H). Anal (C ₁₈ H ₂₂ BrNO ₂ · HCl) C, H, N.
[441] Reality upon 79
[442] 3-quinquinridinyl 1- (4-bromophenyl)
[443] Cyclobutanecarboxylate hydrochloride
[444] The title compound was prepared in a similar manner as described in Example 36. 1- (4-bromophenyl) cyclobutanecarbonyl chloride prepared from the compound prepared in Example 10 was refluxed with 3-quinucridinol overnight. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. The yield was 0.46 g (19%); Melting point 222-226 deg. ¹ H NMR (CD ₃ OD) δ 1.73 (m, 2H), 1.82-2.15 (m, 4H), 2.23 (br, 1H), 2.53 (m, 2H), 2.85 (m, 2H), 2.95-3.10 ( m, 2H), 3.20-3.35 (m, 3H), 3.66 (m, 1H), 5.06 (m, 1H), 7.25 (d, 2H), 7.50 (d, 2H). Anal (C ₁₈ H ₂₂ BrNO ₂ · HCl) C, H, N.
[445] Example 80
[446] 3-quinquinridinyl 1-(3-nitrophenyl)
[447] Cyclobutanecarboxylate hydrochloride
[448] The title compound was prepared in a similar manner as described in Example 36. 1-(3-nitrophenyl) cyclobutanecarbonyl chloride prepared from the compound prepared in Example 33 was reacted with 3 -quinucridinol in CH ₂ Cl ₂ for 2 hours. The crude product was chromatographed on silica gel using 90:10 EtOAc-Et ₃ N as eluent. The yield was 0.4 g (26%); Melting point 191-192 캜; ¹ H NMR (CD ₃ OD) δ 1.73-2.29 (m, 7H), 2.62 (m, 2H), 2.94 (m, 2H), 3.02-3.36 (m, 5H), 3.65-3.75 (m, 1H), 5.10 (m, 1 H), 7.60-7.66 (m, 1 H), 7.74-7.78 (m, 1 H), 8.13-8.18 (m, 2 H). Anal (C ₁₈ H ₂₂ N ₂ 0 ₄ HCl) C, H, N.
[449] Example 81
[450] 3-quinquinridinyl 1- (3,4-methylenedioxyphenyl)
[451] Cyclobutanecarboxylate hydrochloride
[452] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 11 and 3-quinucridinol. The amine salt was recrystallized from acetone-ether. Yield was 0.23 g (15%); Melting point 194-195 ° C .; ¹ H NMR (CD ₃ OD) δ 1.70-2.10 (m, 6H), 2.26 (m, 1H), 2.50 (m, 2H), 2.80 (m, 2H), 3.04 (m, 2H), 3.30 (m, 3H), 3.68 (m, 1H), 5.07 (m, 1H), 5.94 (s, 2H), 6.81 (m, 3H). Anal (C ₁₉ H ₂₃ N0 ₄ · HCl) H. N; C: Theory 62.4; Found 61.9.
[453] Example 82
[454] 3-quinucridinyl 1- (2,3-benzophenyl)
[455] Cyclobutanecarboxylate hydrochloride
[456] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 14 and 3-quinucridinol. It was reacted with SOCl ₂ for 1 hour at room temperature. The residue was dissolved in n-hexane and 1 g of oily impurities were separated. 1- (2,3-benzophenyl) cyclobutanecarbonyl chloride was reacted with 3-quinucridinol at 80 ° C. for 6 hours. The crude product was chromatographed using toluene-EtOAc-Et ₃ N of 70: 20: 10 as eluent. Recrystallization of HCl-salt twice from acetone gave 0.4 g (9%); Melting point 172-177 deg. ¹ H NMR (CD ₃ OD) δ 1.02 (m, 1H), 1.38 (m, 1H), 1.82 (m, 2H), 1.98 (m, 2H), 2.29 (m, 1H), 2.78 (m, 3H) , 3.02 (m, 6H), 3.58 (m, 1H), 5.04 (m, 1H), 7.51 (m, 4H), 7.78 (m, 2H), 7.90 (m, 1H). Analysis _{(C 22 H 25 NO 2 ·} HCl) C, H, N.
[457] Example 83
[458] 3-quinquinridinyl 1- (3,4-benzophenyl)
[459] Cyclobutanecarboxylate hydrochloride
[460] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 15 and 3-quinucridinol. It was reacted with SOCl ₂ for 1 hour at room temperature. 1- (3,4-benzophenyl) cyclobutanecarbonyl chloride was reacted with 3-quinucridinol at 85 ° C. overnight. The crude product was chromatographed on silica gel with 70: 20:10 toluene-EtOAc-Et ₃ N. Yield was 1.16 g (38%); Melting point 197-199 ° C .; ¹ H NMR (CD ₃ OD) δ 1.63 (m, 2H), 1.85 (m, 1H), 1.96 (m, 2H), 2.12 (m, 1H), 2.22 (m, 1H), 2.68 (m, 2H) , 2.95 (m, 4H), 3.19 (m, 3H), 3.65 (m, 1H), 5.07 (m, 1H), 7.46 (m, 3H), 7.84 (m, 4H). Analysis _{(C 22 H 25 NO 2 ·} HCl) C, H, N.
[461] Example 84
[462] 3-quinucridinyl 1-(2-thienyl)
[463] Cyclobutanecarboxylate hydrochloride
[464] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 25 and 3-quinucridinol. The crude product was chromatographed on silica gel using 94: 6 toluene-Et ₃ N as eluent. Yield was 0.71 g (22%); Melting point 196-197 ° C .; ¹ H NMR (CDCl ₃ ) δ 1.60-2.15 (m, 6H), 2.38 (m, 1H), 2.57 (m, 2H), 2.81 (m, 2H), 3.03 (m, 2H), 3.28 (m, 3H ), 3.62 (m, 1H), 5.07 (m, 1H), 6.95 (m, 2H), 7.24 (dd, 1H). Anal (C ₁₆ H ₂₁ NO ₂ SHCl) C, H, N.
[465] Example 85
[466] 3-quinucridinyl 1-(3-thienyl)
[467] Cyclobutanecarboxylate hydrochloride
[468] In a similar manner to the method described in Example 36, the title compound was prepared from the compound prepared in Example 26 and 3-quinucridinol. The crude product was subjected to silica gel chromatography using 94: 6 toluene-Et ₃ N as eluent. Yield was 0.57 g (23%); Melting point 200-202 캜; ¹ H NMR (CDCl ₃ ) δ 1.66 (m, 2H), 1.97 (m, 4H), 2.41 (m, 3H), 2.78 (m, 2H), 3.06 (m, 2H), 3.28 (m, 3H), 3.63 (m, 1 H), 5.04 (m, 1 H), 6.98 (dd, 1 H), 7.14 (dd, 1 H), 7.31 (dd, 1 H). Anal (C ₁₆ H ₂₁ NO ₂ SHCl) C, H, N.
[469] Example 86
[470] 2-endo-methyl-3-quinucridinyl 1-
[471] Phenylcyclobutanecarboxylate Hydrochloride
[472] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with 2-methyl-3-quinucridinol at 80 ° C. for 30 hours. The reaction mixture was filtered to separate the two isomers obtained and chromatographed on silica gel using 95: 5 toluene-Et ₃ N as eluent. Nuclear isomers eluted earlier than exo isomers. Yield of nuclear isomer was 0.60 g (32%); Melting point 193-196 캜; ¹ H NMR (D ₂ O) δ 1.51 (d, 3H), 1.76-2.17 (m, 6H), 2.33 (m, 1H), 2.65 (m, 2H), 2.90 (m, 2H), 3.12 (m, 1H), 3.22 (m, 1H), 3.35-3.47 (m, 3H), 4.76 (m, 1H), 7.42 (m, 1H), 7.46-7.54 (m, 4H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[473] Example 87
[474] 2-exo-methyl-3-quinucridinyl
[475] 1-phenylcyclobutanecarboxylate hydrochloride
[476] The yield of exo isomers obtained at the time of synthesis in Example 86 was 0.24 g (13%); Melting point 204-207 ° C ¹ H NMR (D ₂ 0) δ 1.15 (d, 3H), 1.62-1.76 (m, 2H), 1.90-2.19 (m, 4H), 2.36 (m, 1H), 2.68 (m , 2H), 2.92 (m, 2H), 3.21 (m, 2H), 3.29-3.43 (m, 2H), 3.92 (m, 1H), 5.24 (m, 1H), 7.42 (m, 1H), 7.48- 7.54 (m, 4 H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[477] Reality upon 88
[478] 3--endo- (1-azabicyclo [3.3.1] nonyl)
[479] 1-phenylcyclobutanecarboxylate hydrochloride
[480] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarbonyl chloride with 3-hydroxy-1-azabicyclo [3.3.1] nonane at 80 ° C. for 27 hours. . The reaction mixture was filtered to separate the two isomers obtained and chromatographed on silica gel using 95: 5 toluene-Et ₃ N as eluent. Nuclear isomers eluted before exo isomers. Yield of nuclear isomer was 0.21 g (14%); Melting point 223-228 캜; ¹ H NMR (D ₂ 0) δ 1.83-2.01 (m, 5H), 2.09 (m, 2H), 2.21 (q, 1H), 2.40 (s, 1H), 2.62 (m, 2H), 2.87 (m, 2H), 3.27-3.37 (m, 3H), 3.40-3.51 (m, 2H), 3.64 (q, 1H), 5.64 (m, 1H), 7.42 (t, 1H), 7.44-7.53 (m, 4H) . Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[481] Example 89
[482] 3-exo-(1-azabicyclo [3.3.1] nonyl)
[483] 1-phenylcyclobutanecarboxylate hydrochloride
[484] The yield of the exo isomer obtained at the time of synthesis in Example 88 was 0.33 g (21%); Melting point 167-170 ° C .; ¹ H NMR (D ₂ O) δ 1.50 (d, 2H), 1.70-1.82 (m, 2H), 1.98 (m, 1H), 2.13 (m, 2H), 2.24 (s, 1H), 2.37 (m, 1H), 2.65 (m, 2H), 2.88 (m, 2H), 3.10 (q, 1H), 3.20 (d, 1H), 3.26-3.38 (m, 3H), 3.83 (q, 1H), 5.30 (t , 1H), 7.42 (t, 1H), 7.47 (d, 2H), 7.52 (t, 2H). Analysis _{(C 19 H 25 NO 2 ·} HCl) C, H, N.
[485] Example 90
[486] 3 -methylidenequinucridinyl 1-
[487] Phenylcyclobutanecarboxylate Hydrochloride
[488] In a similar manner to the method described in Example 36, the title compound was prepared by reacting 1-phenylcyclobutanecarboxylate hydrochloride with 3-methylidenequinucridinol. The esterification reaction was carried out in CH ₂ Cl ₂ . The crude product was chromatographed on silica gel using 88:12 toluene-Et ₃ N as eluent. Yield was 0.07 g (9%); Melting point 155-157 캜; ¹ H NMR (CDCl ₃ ) δ 1.80-2.10 (m, 7H), 2.25 (m, 1H), 2.52 (m, 2H), 2.76 (m, 3H), 3.18 (m, 5H), 4.09 (m, 2H ), 7.29 (m, 5 H), 12.2 (br, 1 H). Assay (C ₁₉ H ₂₅ NO ₂ .HCl) H, N; C: Theorem 67.94; Found 67.25.
[489] Example 91
[490] 2-(diisopropylamino) ethyl 1-
[491] Phenyl-3-oxocyclobutanecarboxylate hydrochloride
[492] 1-Phenyl-3,3-dimethoxycyclobutanecarboxylic acid (8.5 mmol) and 90% HOAc were refluxed, the reaction mixture was evaporated to take a residue in 0.1 M HCl and Et ₂ 0, and the aqueous layer was extracted with Et ₂ 0 and then dried. 1-phenyl-3 oxocyclobutanecarboxylic acid was prepared by evaporating the (Na ₂ SO ₄ ) organic layer. The crude oxocarboxylic acid was dissolved in DMF (30 mL) and then added to NaH (60% dispersion in mineral oil, 20 mmol, washed twice with hexane) at ambient temperature. After 30 minutes N, N-diisopropyl-2-chloromethylamine (1.8 mmol) was added. After 2 hours, the reaction mixture was partitioned between H ₂ O and toluene. The crude product was subjected to silica gel chromatography using 98: 2 toluene-Et ₃ N as eluent. The oil thus obtained was dissolved in Et ₂ 0 and then HCl (g) / Et ₂ 0 was added to give 0.25 g (10%) of the crystallized product; Melting point 133-135 ° C .; ¹ H NMR (CDCl ₃ ) δ 1.39 (12H), 3.10 (m, 2H), 3.54 (m, 4H), 4.05 (m, 2H), 4.72 (t, 2H), 7.38 (m, 5H), 11.8 ( br, 1H). Analysis _{(C 19 H 27 NO 3 ·} HCl) C, H, N.
[493] Example 92
[494] 2- (diisopropylamino) ethyl 1- (3-aminophenyl)-
[495] Cyclobutanecarboxylate hydrochloride
[496] 2-(diisopropylamino) ethyl 1- (3-nitrophenyl) -cyclobutanecarboxylate hydrochloride (0.2 g, 0.52 mmol) prepared in Example 49 was dissolved in EtOH. Charcoal (25 mg) containing palladium (10%) is added and the mixture is subjected to hydrogenation at atmospheric pressure for 2 hours. The catalyst is then filtered off and the solvent is evaporated. The residue is dissolved in EtOAc and washed with NaOH. The aqueous layer is extracted with EtOAc. The combined organic layers are washed with H ₂ O, dried (MgSO ₄ ) and concentrated to give the free base. It is dissolved in Et ₂ O and HCl (g) / Et ₂ O is added dropwise. The obtained pink crystals were filtered to give 67 mg (36%) of hydrochloride salt having a melting point of 78-88 deg. ¹ H NMR (CD ₃ OD) δ 1.30 (m, 12H), 1.88-2.20 (m, 2H); 2.55 (m, 2H), 2.90 (m, 2H), 3.43 (t, 2H), 3.67 (m, 2H), 4.42 (t, 2H), 7.27-7.55 (m, 4H). Assay (C ₁₉ H ₃₀ N ₂ O ₂ .2HCl) C; H: theory, 8.2; Found, 8.9; N: theory, 7.2; Anal. 6.7.
[497] Example 93
[498] 2- (diisopropylamino) ethyl 1-phenyl-3 -cis-
[499] Hydroxycyclobutanecarboxylate hydrochloride
[500] NaBH ₄ (16 mmol) is added to the 2-(diisopropylamino) ethyl 1 -phenyl-3 -oxocyclobutanecarboxylic acid solution (1.94 mmol) prepared in Example 91 above, maintaining -60 ° C. The reaction mixture is warmed up to room temperature and cooled with 6 M HCl (4 mL). The solvent is evaporated and the remaining oil is partitioned between 2 M NaOH and Et ₂ O. The crude isomeric mixture is purified by silica gel chromatography using CHCl ₃ -MeOH-concentrated ammonia as the eluent in a ratio of 98: 2: 0.2. Pure cis isomers are separated and the solvent is evaporated. The residue is dissolved in Et ₂ O and HCl (g) / Et ₂ O is added to give the product of a colorless oil. Yield was 0.08 g (12%); ¹ H-NMR (CD ₃ OD) δ 1.24 (d, 12H), 2.35 (m, 2H), 3.21 (m, 2H), 3.38 (t, 2H), 3.59 (m, 2H), 4.46 (m, 3H ), 7.29 (m, 5 H). Anal (C ₁₉ H ₃₀ ClNO ₃ .0.5H ₂ O) C, H, N.
[501] III. Arylcyclopentane Carboxylic Acid Ester
[502] Example 94 (Departures)
[503] 1-(2-thienyl) cyclopentanecarboxylic acid
[504] NaH (80% dispersion in mineral oil, 127 mmol) is washed several times with n-pentane and suspended in DMF. A mixture of 1- (2-thienyl) acetonitrile (60 mmol) and 1,4-dibromopropane (60 mmol) in DMF is added dropwise. The reaction mixture is stirred for 3 hours at room temperature. Careful addition of H ₂ O decomposes the excess hydride. Extraction with toluene, the organic layer is dried (MgSO ₄ ) and the solvent is evaporated to afford 1- (2-thienyl) cyclopentaneacetonitrile. This was purified by silica gel chromatography using petroleum ether-EtOAc in a ratio of 97: 3 as eluent; ¹ H NMR (CDCl ₃ ) δ 1.94 (m, 4H), 2.12 (m, 2H), 2.50 (m, 2H), 6.96 (dd, 1H), 7.10 (dd, 1H), 7.23 (dd, 1H).
[505] Acetonitrile is refluxed with 15 M KOH (30 mL) in ethylene glycol (70 mL) for 2 hours. It is then cooled to room temperature, ether and H ₂ O are added and the layers are separated. The aqueous layer is oxidized and extracted with ether. The organic layer was dried (MgSO ₄ ) and concentrated to afford the desired carboxylic acid in yield of 5.8 g (49%).
[506] Example 95 (Departures)
[507] 1-(3-thienyl) cyclopentanecarboxylic acid
[508] The title compound is prepared in a similar manner to the preparation of Example 94 from 1-(3 -thienyl) acetonitrile and 1,4-dibromopropane; ¹ H NMR (CDCl ₃ ) δ 1.99 (M, 6H), 2.45 (m, 2H), 7.11 (dd, 1H), 7.29 (dd, 1H), 7.36 (dd, 1H).
[509] The yield of the desired carboxylic acid was 10.5 g (49%).
[510] Example 96 (Departures)
[511] 1-phenyl-3,3-dimethylcyclopentanecarboxylic acid
[512] The title compound is prepared in a similar manner to the preparation of Example 94 from 1-phenylacetonitrile and di-O-p-toluene-sulfonyl-2-dimethyl-1,4-butanediol. The obtained 1-phenyl-3 dimethylcyclopentaneacetonitrile was purified by silica gel chromatography using petroleum ether-EtOAc in a ratio of 97: 3 as eluent; ¹ H NMR (CDCl ₃ ) δ 1.13 (s, 3H), 1.30 (s, 3H), 1.77 (m, 1H), 1.98 (m, 2H), 2.24 (m, 1H), 2.40 (m, 1H), 2.51 (m, 1 H), 7.43 (m, 5 H).
[513] The yield of the desired carboxylic acid was 1.8 g (42%).
[514] Example 97
[515] 2-(diethylamino) ethyl 1-(2-thienyl) cyclopentanecarboxylate
[516] Hydrochloride
[517] 1- (2-thienyl) -cyclopentanecarboxylic acid (3.1 mmol) prepared in Example 94 above was refluxed with SOCl ₂ (0.6 mL) in 4 mL of toluene. After 4 hours, the reaction mixture is evaporated and the residue is dissolved in toluene. 2-Diethylaminoethanol (9.3 mmol) is added and the mixture is stirred at rt overnight. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 95: 5 as eluent. Yield was 0.79 g (76%); Melting point 122-123 deg. ¹ H NMR (CDCl ₃ ) δ 1.28 (t, 6H), 1.75 (m, 4H), 2.13 (m, 2H), 2.50 (m, 2H), 2.92 (m, 4H), 3.22 (m, 2H), 4.60 (t, 2H), 6.95 (dd, 2H), 7.19 (dd, 1H), 12.4 (br, 1H). Anal (C ₁₆ H ₂₅ NO ₂ SHCl) C, H, N.
[518] Example 98
[519] 2-(diethylamino) ethyl 1-(3-thienyl) cyclopentanecarboxylate
[520] Hydrochloride
[521] The title compound is prepared in a similar manner to the preparation of Example 97 from 1-(3-thienyl) cyclopentanecarboxylic acid and 2 -diethylaminoethanol prepared in Example 95. The product was purified by silica gel chromatography using toluene-Et ₃ N as an eluent in a ratio of 97: 3; Melting point 121-122 ° C; ¹ H NMR (CDCl ₃ ) δ 1.25 (t, 6H), 1.72 (m, 4H), 2.01 (m, 2H), 2.45 (m, 2H), 2.87 (m, 4H), 3.19 (t, 2H), 4.57 (t, 2H), 7.03 (dd, 1H), 7.13 (dd, 1H), 7.30 (dd, 1H), 12.3 (br, 1H). Anal (C ₁₆ H ₂₅ NO ₂ SHCl) C, H, N.
[522] Example 99
[523] 2-(diisopropylamino) ethyl 1 -phenylcyclopentanecarboxylate
[524] Hydrochloride
[525] The title compound was prepared in a similar manner to the preparation of Example 97 by reacting 1-phenylcyclopentanecarbonyl chloride and 2-diisopropylaminoethanol at 80 ° C. for 8 hours. The reaction mixture was filtered and purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 95: 5 as eluent. Yield was 1.5 g (78%); Melting point 124-128 ° C .; ¹ H NMR (D ₂ O) δ 1.31 (d, 12H), 1.79 (m, 4H), 2.12 (m, 2H), 2.58 (m, 2H), 3.45 (t, 2H), 3.67 (m, 2H) , 4,43 (t, 2H), 7.4 (m, 1H), 7.48-7.54 (m, 4H). Anal (C ₂₀ H ₃₁ NO ₂ HCl) C, H, N.
[526] Example 100
[527] 2-(diisopropylamino) ethyl 1- (2-thienyl)
[528] Cyclopentanecarboxylate hydrochloride
[529] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(2-thienyl) cyclopentanecarboxylic acid and 2-diisopropylaminoethanol prepared in Example 94. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 98: 2 as eluent. Yield was 0.6 g (54%); Melting point 147-148 deg. ¹ H NMR (CDCl ₃ ) δ 1.42 (m, 12H), 1.76 (m, 4H), 2.11 (m, 2H), 2.52 (m, 2H), 3.09 (m, 2H), 3.57 (m, 2H), 4.71 (t, 2H), 6,94 (m, 2H), 7.20 (dd, 1H), 11.7 (br, 1H). Anal (C ₁₈ H ₂₉ NO ₂ SHCl) C, H, N.
[530] Example 101
[531] 2-(diisopropylamino) ethyl 1-(3-thienyl)-
[532] Cyclopentanecarboxylate
[533] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(3-thienyl) cyclopentanecarboxylic acid and 2 -diisopropylaminoethanol prepared in Example 95. The product was purified by silica gel chromatography using toluene-Et ₃ N as an eluent in a ratio of 97: 3. Yield was 0.99 g (66%); Melting point 126-127 deg. ¹ H NMR (CDCl ₃ ) δ 1.39 (m, 12H), 1.71 (m, 4H), 2.00 (m, 2H), 2.49 (m, 2H), 3.06 (m, 2H), 3.55 (m, 2H), 4.68 (t, 2H), 7.03 (dd, 1H), 7.12 (dd, 1H), 7.28 (dd, 1H), 11.7 (br, 1H). Anal (C ₁₈ H ₂₉ NO ₂ SHCl) C, H, N.
[534] Example 102
[535] (1-Methyl-3-piperidino) methyl 1- (2-thienyl)-
[536] Cyclopentanecarboxylate hydrochloride
[537] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(2 -thienyl) cyclopentanecarboxylic acid and (1 -methyl-3 -piperidino) methanol prepared in Example 94. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 95: 5 as eluent. Yield was 0.94 g (88%); Melting point 134-135 ° C .; ¹ H NMR (CDCl ₃ ) δ 1.04 (m, 1H), 1.74 (m, 6H), 2.03-2.65 (m, 11H), 3.12 (d, 1H), 3.40 (d, 1H), 4.03 (m, 2H ), 6.98 (dd, 2H), 7.21 (dd, 1H), 12.3 (br, 1H). Anal (C ₁₇ H ₂₅ NO ₂ SHCl) C, H, N.
[538] Example 103
[539] (1 -Methyl-3 -piperidino) methyl 1-(3-thienyl)-
[540] Cyclopentanecarboxylate hydrochloride
[541] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(3 -thienyl) cyclopentanecarboxylic acid and (1 -methyl-3 -piperidino) methanol prepared in Example 95. The product was purified by silica gel chromatography using toluene-Et ₃ N as an eluent in a ratio of 97: 3. Yield was 0.82 g (57%); Melting point 156-157 캜; ¹ H NMR (CDCl ₃ ) δ 0.99 (m, 1H), 1.65-3.65 (m, 17H), 3.07 (d, 1H), 3.39 (d, 1H), 4.00 (m, 2H), 7.08 (dd, 1H ), 7.16 (dd, 1H), 7.29 (dd, 1H), 12.4 (br, 1H). Anal (C ₁₇ H ₂₅ NO ₂ SHCl) C, H, N.
[542] Example 104
[543] 1-Methyl-4-piperidinyl 1- (2-thienyl)-
[544] Cyclopentanecarboxylate hydrochloride
[545] The title compound was prepared in a similar manner to the preparation of Example 97 from 1- (2-thienyl) cyclopentanecarboxylic acid and 1-methyl-4-hydroxypiperidine prepared in Example 94. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 96: 4 as the eluent. Yield was 0.97 g (47%); Melting point 164-165 deg. ¹ H NMR (CDCl ₃ ) δ 1.77 (s, 4H), 1.93 (m, 2H), 2.13 (m, 2H), 2.49 (m, 6H), 2.62 (s, 3H), 3.20 (m, 2H), 5.01 (s, 1 H), 6.97 (m, 2 H), 7.22 (d, 1 H). Anal (C ₁₆ H ₂₃ NO ₂ SHCl) C, H, N.
[546] Example 105
[547] 1-Methyl-4-piperidinyl 1- (3-thienyl)-
[548] Cyclopentanecarboxylate hydrochloride
[549] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(3-thienyl) cyclopentanecarboxylic acid and 1 -methyl-4 -hydroxypiperidine prepared in Example 95. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 96: 4 as the eluent. Yield was 0.88 g (32%); Melting point 163-164 deg. ¹ H NMR (CDCl ₃ ) δ 1.74-2.62 (m, 17H), 3.14 (s, 2H), 4.98 (s, 1H), 7.05 (dd, 1H), 7.15 (d, 1H), 7.30 (d, 1H ), 12.3 (br, 1H). Anal (C ₁₆ H ₂₃ NO ₂ SHCl) C, H, N.
[550] Example 106
[551] 3-quinucridinyl 1-phenylcyclopentanecarboxylate hydrochloride
[552] The title compound was prepared in a similar manner to the preparation of Example 97 by reacting 1-phenylcyclopentanecarbonyl chloride with 3-quinucridinol at 80 ° C. for 22 hours. The reaction mixture was filtered and purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 95: 5 as eluent. Yield was 0.7 g (41%); Melting point 201-203 ° C .; ¹ H NMR (D ₂ O) δ 1.79 (m, 6H), 1.92 (m, 1H), 2.07 (m, 3H), 2.34 (m, 1H), 2.66 (m, 2H), 3.04 (q, 1H) , 3.13 (d, 1H), 3.25-3.37 (m, 3H), 3.67 (m, 1H), 5.13 (m, 1H), 7.41 (t, 1H), 7.48 (t, 2H), 7.53 (d, 2H ). Anal (C ₁₉ H ₂₅ NO ₂ SHCl) C, H, N.
[553] Example 107
[554] 3-quinucridinyl 1- (2-thienyl) -cyclopentanecarboxylate hydrochloride
[555] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(2-thienyl) cyclopentanecarboxylic acid and 3-quinucridinol prepared in Example 94. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 96: 4 as the eluent. Yield was 0.2 g (13%); Melting point 209-211 캜; ¹ H NMR (CDCl ₃ ) δ 1.55-2.26 (m, 10H), 2.38 (m, 1H), 2.46 (m, 2H), 3.02 (m, 2H), 2.27 (m, 3H), 3.50 (m, 1H ), 5.02 (m, 1 H), 6.94 (dd, 2 H), 7.21 (dd, 1 H). Anal (C ₁₇ H ₂₃ NO ₂ SHCl) C, H, N.
[556] Example 108
[557] 3-quinukridinyl 1- (3-thienyl) -cyclopentanecarboxylate
[558] Hydrochloride
[559] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(3-thienyl) cyclopentanecarboxylic acid and 3-quinucridinol prepared in Example 95. Arylcyclopentanecarbonyl chloride is refluxed with 3-quinucridinol for 3 days. The product was purified by silica gel chromatography using toluene-Et ₃ N as an eluent at a ratio of 89:11. Yield was 1.73 g (40%); Melting point 213-215 deg. ¹ H NMR (CDCl ₃ ) δ 1.61-2.11 (m, 10H), 2.32 (m, 1H), 2.49 (m, 2H), 2.99 (m, 2H), 3.27 (m, 3H), 3.58 (m, 1H ), 5.00 (m, 1H), 7.02 (dd, 1H), 7.13 (dd, 1H), 7.28 (dd, 1H), 12.3 (br, 1H). Anal (C ₁₇ H ₂₃ NO ₂ SHCl) C, H, N.
[560] Example 109
[561] 3--endo- (1 -azabicyclo [3.3.1] nonyl) 1-phenylcyclo-
[562] Pentanecarboxylate hydrochloride
[563] The title compound was prepared in a similar manner to the preparation of Example 97 by reacting 1-phenylcyclopentanecarbonyl chloride with 3-hydroxy-1-azabicyclo [3.3.1] nonane at 80 ° C. for 18 hours. The reaction mixture was filtered and purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 95: 5 as eluent to separate the two isomers obtained. Endo isomers escape faster than exo isomers. The yield of the endo isomer was 90 mg (7%); Melting point 242-246 ° C .; ¹ H NMR (D ₂ O) δ 1.68-1.88 (m, 7H), 1.88-2.08 (m, 4H), 2.14 (m, 1H), 2.36 (s, 1H), 2.55 (m, 2H), 3.25 ( m, 3H), 3.42 (m, 2H), 3.55 (m, 1H), 5.55 (m, 1H), 7.39 (m, 1H), 7.47 (m, 4H). Anal (C ₂₀ H ₂₇ NO ₂ SHCl) C, H, N.
[564] Example 110
[565] 3-exo-(1-azabicyclo [3.3.1] nonyl) 1-phenylcyclo-
[566] Pentanecarboxylate hydrochloride
[567] The yield of the exo isomer synthesized in Example 109 was 200 mg (16%); Melting point 195-198 ° C .; ¹ H NMR (D ₂ O) δ 1.42 (m, 2H), 1.68-1.85 (m, 6H), 2.02-2.16 (m, 3H), 2.22 (s, 1H), 2.36 (m, 1H), 2.58 ( m, 2H), 3.02 (q, 1H), 3.18 (d, 1H), 3.23-3.32 (m, 3H), 3.82 (q, 1H), 5.25 (t, 1H), 7.40 (t, 1H), 7.45 -7.52 (m, 4 H). Analysis _{(C 20 H 27 NO 2 ·} HCl) C, H, N.
[568] Example 111
[569] 3-Tropanyl 1- (2-thienyl) cyclopentane-carboxylate
[570] Hydrochloride
[571] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-(2-thienyl) cyclopentanecarboxylic acid and 3-tropanol prepared in Example 94. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 93: 7 as the eluent. Yield was 0.94 g (28%); Melting point 236-237 deg. ¹ H NMR (CDCl ₃ ) δ 1.74 (m, 8H), 2.08 (m, 4H), 2.48 (m, 2H), 2.70 (s, 3H), 2.97 (d, 2H), 3.66 (m, 2H), 5.08 (m, 1 H), 6.95 (dd, 2 H), 7.19 (dd, 1 H). Anal (C ₁₈ H ₂₅ NO ₂ SHCl) C, H, N.
[572] Example 112
[573] 2-(diisopropylamino) ethyl 1 -phenyl-3,3-
[574] Dimethylcyclopentanecarboxylate Hydrochloride
[575] The title compound was prepared in a similar manner to the preparation of Example 97 from 1-phenyl-3,3-dimethylcyclopentanecarboxylic acid and 2-diisopropylaminoethanol prepared in Example 96. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 98: 2 as eluent. Yield was 0.83 g (52%). Hydrochloride salts are obtained as colorless oils; ¹ H NMR (CDCl ₃ ) δ 1.00 (s, 3H), 1.08 (s, 3H), 1.34 (m, 12H), 1.54 (m, 2H), 1.87 (d, 1H), 2.11 (m, 1H), 2.66 (m, 2H), 2.98 (m, 2H), 3.49 (m, 2H), 4.64 (t, 2H), 7.28 (m, 5H), 11.5 (br, 1H). Analysis _{(C 22 H 35 NO 2 ·} HCl) C, H, N.
[576] Ⅳ. Arylcyclohexane Carboxylic Acid Ester
[577] Example 113 (Departure Material)
[578] 1-Phenyl-4-methoxycyclohexanecarboxylic acid
[579] NaBH ₄ (20 mmol) in H ₂ O (7 mL) is added to a solution of 4-cyano-4-phenylcyclohexanone (25 mmol) in THF. The reaction mixture is stirred at rt for 3 h and then cooled with HOAc. The filtered solution is evaporated and the remaining residue is placed in Et ₂ O / Salt. The resulting alcohol is dissolved in THF and dropped dropwise into a suspension of NaH (24.5 mmol) washed several times with hexane. After stirring for 30 minutes, Mel (26 mmol) is added carefully, then the mixture is stirred for 5 minutes and evaporated. The residue is taken up in Et ₂ O / salts and the organic layer is dried (MgSO ₄ ) and then evaporated. The remaining oil is refluxed with KOH (25%, 300 mL) in ethylene glycol (250 mL) for 3 days. The cooled solution is washed with Et ₂ O. The aqueous layer is oxidized with concentrated HCl and extracted with Et ₂ O. The organic layer was dried and evaporated to afford 4.6 g of the desired product; ¹ H NMR (CDCl ₃ ) δ 1.51-1.73 (m, 4H), 2.02 (m, 2H), 2.64 (m, 2H), 3.21 (m, 1H), 3.35 (s, 3H), 7.20-7.45 (m , 5H), 10.2 (br, 1H).
[580] Example 114 (Departures)
[581] 1-Phenyl-4-oxocyclohexanecarboxylic acid
[582] 4-cyano-4-phenylcyclohexanone (25 mmol) with Dean-Stark trap
[583] Stark trap) is refluxed with toluenesulfonic acid (2.5 mmol) and ethylene glycol (30 mmol) in toluene (150 mL) for 2 hours. The reaction mixture is partitioned between Et ₂ O and 2 M NaHCO ₃ . The organic layer is dried (Na ₂ SO ₄ ) and evaporated. The remaining oil is refluxed with KOH (40%, 200 mL) in ethylene glycol (120 mL) for 3 hours. Conc. HCl is added and the mixture is cooled. Then extracted with Et ₂ O, dried (Na ₂ SO ₄ ) and evaporated to afford 4.4 g (81%) of the desired compound; ¹ H NMR (CDCl ₃ ) δ 2.2-2.5 (m, 4H), 2.55 (m, 2H), 2.74 (m, 2H), 7.25-7.50 (m, 5H), 8.0 (br, 1H).
[584] Example 115 (Departure Material)
[585] 1-Phenyl-3,3-dimethylcyclohexanecarboxylic acid
[586] NaH (60% dispersion in mineral oil, 72.3 mmol) is washed several times with n-hexane and suspended in DMF. A mixture of phenylacetonitrile (24.1 mmol) and di-0-p-toluene-sulfonyl-2-dimethyl-1,5-pentanediol (24.1 mmol) in DMF is added dropwise. The reaction mixture is stirred at 70 ° C. for 3 hours and the DMF is evaporated under low pressure. Excess hydride is decomposed by the careful addition of H ₂ O. Extraction with Et ₂ O, drying the organic layer (MgSO ₄ ) and evaporation of the solvent gave 1-phenyl-3,3-dimethylcyclohexaneacetonitrile as eluent and petroleum ether-EtOAc in a ratio of 98: 2. Purification by chromatography; ¹ H NMR (CDCl ₃ ) δ 0.96 (s, 3H), 1.26 (m, 1H), 1.31 (m, 3H), 1.59 (m, 2H), 1.78 (m, 2H), 1.92 (m, 2H), 2.23 (m, 1 H), 7.49 (m, 5 H).
[587] 7.0 mmol nitrile is refluxed with KOH (40%, 15 mL) in ethylene glycol (40 mL) for 2 days. It is then cooled to room temperature and extracted with Et ₂ O. The aqueous layer is oxidized and extracted with Et ₂ O. The organic layer was dried (MgSO ₄ ) and concentrated to yield 1.5 g (27%) of the desired carboxylic acid.
[588] Example 116 (Departures)
[589] 1-Phenyl-4,4-dimethylcyclohexanecarboxylic acid
[590] The title compound was prepared in a similar manner to the preparation of Example 113. 1-Phenyl-4, 4-dimethylcyclohexaneacetonitrile is refluxed with KOH in ethylene glycol for 2 hours. The yield of the desired carboxylic acid was 0.55 g (12%); ¹ H NMR (CDCl ₃ ) δ 0.94 (s, 3H), 1.00 (s, 3H), 1.49 (m, 2H), 1.74 (m, 2H), 1.92 (m, 4H), 7.44 (m, 5H).
[591] Example 117
[592] 2-(diisopropylamino) ethyl 1 -phenylcyclohexane-
[593] Carboxylate hydrochloride
[594] 1-Phenyl-cyclohexanecarboxylic acid (1 g, 4.9 mmol) is refluxed with SOCl ₂ (15 mL). After 0.5 h, the reaction mixture is evaporated and the remaining residue is dissolved in toluene. 2 -diisopropylaminoethanol (1.4 g, 9.8 mmol) is added and the mixture is stirred at 80 ° C for 14 h. The reaction mixture was filtered and purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 95: 5 as the eluent. Yield was 1.5 g (84%); Melting point 119-122 ° C .; ¹ H NMR (D ₂ O) δ 1.38 (d, 12H), 1.40 (m, 1H), 1.54 (m, 2H), 1.63-1.76 (m, 3H), 1.95 (t, 2H), 2.45 (d, 2H), 3.44 (t, 2H), 3.67 (m, 2H), 4.44 (t, 2H), 7.43 (t, 1H), 7.51 (t, 2H), 7.54 (d, 2H). Analysis _{(C 21 H 33 NO 2 ·} HCl) C, H, N.
[595] Example 118
[596] 2-(diisopropylamino) ethyl 1 -phenyl-4-
[597] Methoxycyclohexanecarboxylate hydrochloride
[598] The title compound was prepared in a similar manner to the preparation of Example 117 from 1 -phenyl-4 -methoxycyclohexanecarboxylic acid and 2 -diisopropylaminoethanol prepared in Example 113. The reaction mixture with SOCl _{2 is} refluxed for 2 hours. Yield was 1.79 g (57%); Melting point 129-134 캜; ¹ H NMR (CD ₃ OD) δ 1.24 (d, 12H), 1.42 (2H), 1.80 (m, 2H), 2.01 (m, 2H), 2.60 (m, 2H), 3.20-3.40 (m, 6H) , 3.59 (m, 2H), 4.42 (t, 2H), 7.20-7.44 (m, 5H). Analysis _{(C 22 H 35 NO 3 ·} HCl) C, H, N.
[599] Example 119
[600] 2-(diisopropylamino) ethyl 1 -phenyl-4-
[601] Oxocyclohexanecarboxylate hydrochloride
[602] The title compound was prepared in a similar manner to the preparation of Example 117 from 1 -phenyl-4 oxocyclohexanecarboxylic acid and 2 -diisopropylaminoethanol prepared in Example 114. The amine salt is recrystallized from acetone / Et ₂ O.
[603] Yield was 0.28 g (28%); Melting point 158-162 deg. ¹ H NMR (CD ₃ OD) δ 1.25 (m, 12H), 1.57-2.08 (m, 4H), 2.40 (m, 3H), 2.66 (m, 1H), 3.36 (m, 2H), 3.59 (m, 2H), 4.44 (m, 2H), 7.20-7.55 (m, 5H). Analysis _{(C 21 H 31 NO 3 ·} HCl) C, H, N.
[604] Example 120
[605] 3-quinucridinyl 1-phenylcyclohexanecarboxylate hydrochloride
[606] The title compound was prepared in a similar manner to the preparation of Example 117 by reacting 1-phenylcyclohexanecarbonyl chloride with 3-quinucridinol at 80 ° C. for 25 hours. The reaction mixture was filtered and purified by silica gel chromatography using toluene-Et ₃ N in an eluent of 95: 5. Yield was 0.55 g (31%); Melting point 215-220 ° C .; ¹ H NMR (D ₂ O) δ 1.38 (m, 1H), 1.53 (q, 2H), 1.62-1.82 (m, 5H), 1.94 (m, 3H), 2.07 (m, 1H), 2.34 (s, 1H), 2.48 (m, 2H), 3.03 (q, 1H), 3.51 (d, 1H), 3.26-3.39 (m, 3H), 3.69 (q, 1H), 5.18 (m, 1H), 7.41 (t , 1H), 7.50 (t, 2H), 7.57 (d, 2H). Analysis _{(C 20 H 27 NO 2 ·} HCl) C, H, N.
[607] Example 121
[608] 3-quinucridinyl 1-phenyl-4-methoxycyclo-
[609] Hexanecarboxylate Hydrochloride
[610] The title compound was prepared in a similar manner to the preparation of Example 117 from 1 -phenyl-4 -methoxycyclohexanecarboxylic acid and 3 -quinucridinol prepared in Example 113. The reaction mixture with SOCl _{2 is} refluxed for 2 hours. 1-Phenyl-4-methoxycyclohexanecarbonyl chloride is reacted with 3-quinucridinol at 50 ° C. for 15 hours. Yield was 0.69 g (18%); Melting point 189-203 캜; ¹ H NMR (CD ₃ OD) δ 1.47 (m, 2H), 1.65-2.15 (m, 8H), 2.26 (m, 1H), 2.68 (m, 2H), 2.99 (m, 2H), 3.20-3.42 ( m, 7H), 3.70 (m, 1H), 5.11 (m, 1H), 7.18-7.45 (m, 5H). Analysis _{(C 21 H 29 NO 3 ·} HCl) C, H, N.
[611] Example 122
[612] 3-quinucridinyl 1-phenyl-4oxocyclo-
[613] Hexanecarboxylate Hydrochloride
[614] The title compound was prepared in a similar manner to the preparation of Example 117 by reacting 1-phenyl-4-oxocyclohexanecarboxylic acid and 3-quinucridinol prepared in Example 114 at 50 ° C. for 15 hours. The amine salt was recrystallized from acetone / Et ₂ O to give 0.11 g (2%); Melting point 248-251 ° C .; ¹ H NMR (CD ₃ OD) δ 1.68 (m, 3H), 1.92 (m, 3H), 2.22 (m, 1H), 2.31-2.63 (m, 5H), 2.78 (m, 1H), 2.97 (m, 2H), 3.20 (m, 3H), 3.70 (m, 1H), 5.12 (m, 1H), 7.16-7.59 (m, 5H). Analysis _{(C 20 H 25 NO 3 ·} HCl) C, H, N.
[615] Example 123
[616] 2-(isopropylamino) ethyl 1 -phenylcyclo-
[617] Hexanecarboxylate Hydrochloride
[618] The title compound was prepared in a similar manner to the preparation of Example 117 by reacting 1-phenylcyclohexanecarbonyl chloride (2.69 mmol) with BOC-protected isopropylaminoethanol (2.69 mmol) and pyridine (2.69 mmol) overnight at room temperature. It was. The solvent is evaporated and the residue is dissolved in EtOAc. 3 M HCl is added and the reaction mixture is stirred overnight. The combined organic layers are dried (MgSO ₄ ) and concentrated in vacuo. 0.1 g of the free base obtained by purification by silica gel chromatography using hexane-Et ₃ N in an eluent ratio of 90:10 was dissolved in Et ₂ O and HCl (g) / Et ₂ O was added dropwise. Filtration gave 0.09 g (11%) of hydrochloride salt; Melting point 187-190 ° C .; ¹ H NMR (CD ₃ OD) δ 1.20 (d, 6H), 1.26-1.85 (m, 8H), 2.47-2.52 (m, 2H), 3.06-3.16 (m, 1H), 3.22 (t, 2H), 4.30 (t, 2 H), 7.21-7.44 (m, 5 H). Anal (C ₁₈ H ₂₇ NO ₂ HCl) C, H, N.
[619] Example 124
[620] 2- (diisopropylamino) ethyl 1-phenyl-4,4-
[621] Dimethylcyclohexanecarboxylate Hydrochloride
[622] The title compound was obtained by the method similar to the preparation of Example 117 from 1-phenyl-4,4-dimethylcyclohexanecarboxylic acid and 2-diisopropylaminoethanol prepared in Example 116. The product was purified by silica gel chromatography using toluene-Et ₃ N in a ratio of 99: 1. The residue was dissolved in petroleum ether and the product obtained by adding HCl / ether diluted with petroleum ether was recrystallized to give 0.29 g (39%); Melting point 128-129 deg. ¹ H NMR (CDCl ₃ ) δ 0.89 (s, 3H), 0.94 (s, 3H), 1.34 (m, 16H), 1.89 (m, 2H), 2.38 (m, 2H), 2.99 (m, 2H), 3.49 (m, 2H), 4.68 (t, 2H), 7.22-7.42 (m, 5H), 11.6 (br, 1H). Anal (C ₂₃ H ₃₇ NO ₂ · HCl) C, H, N.
[623] Example 125
[624] 2- (diisopropylamino) ethyl 1-phenyl-3, 3-dimethylcyclohexanecarboxylate
[625] The title compound was prepared in a similar manner to the preparation of Example 117 from 1-phenyl-3,3-dimethylcyclohexanecarboxylic acid and 2-diisopropylaminoethanol prepared in Example 115. The product was purified by silica gel chromatography using toluene-Et ₃ N as an eluent at a ratio of 98: 2. The residue was dissolved in petroleum ether and the product obtained by adding HCl (g) / Et ₂ O diluted with petroleum ether was recrystallized to give 0.82 g (44%); Melting point 167-169 ° C .; ¹ H NMR (CDCl ₃ ) δ 0.86 (s, 3H), 0.92 (s, 3H), 1.30 (m, 15H), 1.72 (m, 3H), 2.41 (d, 1H), 2.58 (m, 1H), 3.00 (m, 2H), 3.48 (m, 2H), 4.62 (m, 2H), 7.34 (m, 5H), 11.6 (br, 1H). Analysis _{(C 23 H 37 NO 2 ·} HCl) C, H, N.
[626] Example 126
[627] 2- (diisopropylamino) ethyl 1-phenyl-4,4-
[628] Ethylenedioxycyclohexanecarboxylate Hydrochloride
[629] 1-Phenyl-4-oxocyclohexanecarboxylic acid 2- (diisopropylamino) ethyl hydrochloride (3 mmol) prepared in Example 119 was added to p-toluenesulfonic acid in toluene (50 mL) using a Dean-Stark trap. 1.5 mmol) and ethylene glycol (4 mmol) for 4 hours. The reaction mixture is partitioned between Et ₂ O and 2 M NaHCO ₃ . The organic layer is dried (Na ₂ SO ₄ ) and evaporated. The residue is dissolved in Et ₂ O and HCl (g) / Et ₂ O is added. The amine salt was recrystallized from acetone / Et ₂ O to give 0.53 g (43%); Melting point 121-128 ° C; ¹ H NMR (CD ₃ OD) δ 1.25 (d, 12H), 1.72 (m, 4H), 2.13 (m, 2H), 2.47 (m, 2H), 3.35 (t, 2H), 3.59 (m, 2H) , 3.93 (m, 4H), 4.42 (t, 2H), 7.26-7.47 (m, 5H).
[630] Preparation of pharmaceutical composition
[631] Example A: 5 mg tablets
[632] Standard raw material needed for 1000 tablets
[633] I active compound, mesh * 70 lactosium, Ph. Nordamylium Midas, Ph. Nord5 g210 g75 g II Collidone 25 B.S.F.Water Purifying Agent3.5 g sufficient quantity III degreasing, Ph. Nordmagnesi Stearas, Ph. No-road15 g1.5 g Weight of 1000 tablets1 Weight of correction325 g325 mg
[634] * Mesh standard is according to international system of code DIN 4189/1968.
[635] Punch: Beveled edge with a uniform line around 10.5 mm.
[636] The encapsulated material I is thoroughly mixed and then wetted with material II to granulate the mixture through a stainless filter 10 (25 mesh). The particles are dried in an oven at a temperature of up to 40 ° C. and then filtered through filter 10 repeatedly. Add material III and mix thoroughly. Take out tablets with a total weight of about 325 mg.
[637] Example B: Suspension for 5 mg / ml Injection
[638] Active compound, mesh 1005 mg Sodium chloride8 mg Carboxy Methyl Cellulose1 mg Benzyl alcohol1 mg Distilled water1 ml
[639] Example C: Oral Suspension 1 mg / ml
[640] Active compound, mesh 1001 mg Sorbitol600 mg SpicesFill coloring agentFill water1 ml
[641] Example D: 5 mg suppositories
[642] Active compound5 mg Coconut oilFill
[643] Example E: Ointment 1%
[644] Active compound1 g Triethanolamine1 g Glycerol7 g Cetanol2.5 g lanolin2.5 g Stearic acid20 g Sorbitan monooleate0.5 g Sodium hydroxide0.2 g Methyl paraben0.3 g Profile paraben0.1 g ethanol0.9 g water100 g
[645] Example F: 2 mg capsules
[646] Active compound2 mg Magnesium stearate2 mg Tallinn188 mg
[647] Mix the materials and place in capsules.
[648] Example G: Sterilized to be dissolved in water for use as an injection
[649] Powder 5 mg
[650] Water soluble active compound2 mg Sodium chloride2 mg Methyl paraben0.7 mg Profile paraben0.3 mg
[651] The materials are dissolved in distilled water. The solution is divided into vials and lyophilized.
[652] Example H: 5 mg / ml injection solution
[653] Water soluble active compound5 mg Ascorbic acid1 mg Sodium bisulfite1 mg Sodium chloride6 mg Methyl paraben0.7 mg Profile paraben0.3 mg Distilled water1 ml
[654] In Examples A-H described above in connection with the composition, the active compound is wrapped by acid addition salts made by the addition of the general formulas I and IA or pharmaceutically acceptable inorganic or organic acids described above. Water-soluble active compounds are the acid addition salts described above, or salts with pharmaceutically acceptable inorganic or organic cations. In addition, two or more active compounds of the present invention may be used in a composition as described or in admixture with other pharmaceutically active ingredients, if desired.
[655] Biological assessment
[656] The pharmacological activity of the compounds prepared in the examples was examined using other methods in vitro.
[657] Receptor binding test
[658] Tissue specimens and general methods used are described in detail herein in the case of parotid ¹ , heart ² and cerebral cortex ³ respectively. Male guinea pigs (250-400 g body weight) are killed and collected before blood collection. The brain is placed on ice for the incision of the cerebral cortex (gray part only). The heart and parotid gland are dissected in Krebs-Henseleit buffer (pH 7.4) containing 1 mM fluorinated phenyl methyl sulfonyl (PMSF, protease inhibitor). The incised tissue is ground in a cold sodium phosphate-potassium containing 1 mM PMSF using a Polytron PT-10 instrument (heart, parotid gland) and a Potter-Elbezem Teflon grinder (cortex). The ground tissue is diluted with cold phosphate / PMSF buffer to a protein concentration of 0.3 mg / ml or less, followed by immediate receptor binding test. Protein is measured by the method (1951) ⁴ used by Lowry et al. Using bovine serum albumin as a sample. The muscarinic receptor affinity of the compounds of the unlabeled examples showed receptor specific binding of (-) ³ H -QNB (1-quinucridinyl [henyl-4- ³ H] benzate, 32-52 ci / mmole) The ability to inhibit was obtained from competitive trials in which ^{3 and 5} investigations were described, as described in the references. Each sample contains 10 μl of (−) ³ H −QNB (final concentration 2 nM), 10 μl of test compound solution and 1.0 ml of ground tissue placed in 24-well cell culture medium. Three specimens are incubated at equilibrium conditions, ie, 25 ° C. for 100 minutes (heart and brain cortex) or 240 minutes (sub-line), respectively. Nonspecific binding is measured in the presence of 10 μM of unlabeled atropine. Incubation is terminated by filtration using FilterMate-196 and GF / B-unifilters and radioactivity is measured by a filtration liquid scintillation spectrometer.
[659] IC ₅₀ − value [concentration of unlabeled compound causing 50% inhibition of (−) ³ H −QNB specific binding receptor] is determined graphically by experimental concentration—inhibition curve. Affinity expressed as dissociation constant K _i is calculated by collecting IC ₅₀ values for radioligand-induced parallel transformation and change in receptor concentration using Jacobs et al. (1976) ⁶ . Binding parameters for (−) ³ H -QNB (K _D and receptor density) used in these calculations are determined by each of Experiments ^1-3 .
[660] This method has changed from centrifugal assay to filtration assay. To confirm the filtration assay, the K _i -values of atropine, AF-DX 116, 4-DAMP and pyrenzepine were compared to the K _i -values measured using a centrifugation assay. The K _i -values of these two methods are almost identical (within experimental error). Incubation time is extended by 20-40 minutes due to the slow process up to 25 ° C in this sample.
[661] Study in vitro
[662] Male guinea pigs weighing about 300 g were bled and collected. Soft muscle tissue of the bladder is excised in Krebs-Hensley buffer (pH 7.4). Tissue specimens are placed vertically between the two rings in a tracheal vessel (5 ml) that is thermostated (37 ° C.). One ring is adjustable and connected to an energy converter (FT 03, grass instrument). This Krebs-Hensley buffer solution is continuously bubbled with carbogen gas (93.5% O ₂ /6.5% CO ₂ ) to maintain pH at 7.4. Isometric tension is recorded by glass polygraph (model 97D). A resting tension of about 5 mN is first applied to each muscle tissue and the specimen is allowed to settle for at least 45 minutes. The resting tension is adjusted repeatedly and the specimens are washed several times during the stabilisation period.
[663] Carbacol (chloride carbamylcholine) is used as a reference muscarinic receptor antagonist. In each experiment, the viability of the specimen and the resilience to the contractile response of the specimen were initially measured by two successive additions of carbacol at the maximum concentration (3 × 10 ⁻⁶ M). Concentration-response curves for carbacol are obtained following incremental addition of carbacol to the tracheal vessel (ie, gradual increase of inhibitor concentration until reaching the maximum contraction reaction) and given a rest period of at least 15 minutes. . The test compound (inhibitor) is added to the trachea-container before recovery. After 60 minutes of incubation with the antagonist, a second incremental concentration-response curve for carbacol is obtained. The response is expressed as a percentage of the maximum response to carbacol. In the absence of antagonists (control sample) and in the presence of antagonists, the EC ₅₀ − value of carbacol can be found graphically and the dosage ratio (r) can be calculated. The dissociation constant for the inhibitor, K _B, is calculated using Equation (1) ⁷ .
[664] K _B = [A] / r-1 (1)
[665] Where [A] is the concentration of the test compound.
[666] For each case of the heart (M ₂ receptor), parotid gland (M ₃ receptor) and cortex (M ₁ receptor), the K _i values obtained in the receptor binding assay and the K _B values obtained in the in vitro action study are shown in the table below. 1 to 4 are shown.
[667] This in vitro study of glycolysis was also performed on a sample of small intestine muscles instead of the soft bladder muscles of guinea pigs. The obtained K _B values are shown in Table 5 below.
[668] TABLE 1
[669] Arylcyclopropane Carboxylic Acid Ester
[670] Example Number of CompoundsK _B (nM)K _i M ₁ (nM)K _i M ₂ (nM)K _i M ₃ (nM) 4185.716099 52601050160 67.05.73521 7264.31641 8390695201200 Atropine (Control)0.70.30.90.9 Oxybutynin (Control)4.40.412.80.62
[671] TABLE 2
[672] Arylcyclobutane Carboxylic Acid Ester
[673]
[674] Table 2 (continued)
[675]
[676] TABLE 3
[677] Arylcyclopentane Carboxylic Acid Ester
[678]
[679] TABLE 4
[680] Arylcyclohexane Carboxylic Acid Ester
[681]
[682] TABLE 5
[683] Example Number of CompoundsK _B (nM) 993.9 1170.41 Dalifenacin (Control)To 10
[684] As shown in the table, the compounds tested exhibit high activity and specificity as antagonists for muscarinic receptor mediated bladder contractions. They also show high affinity and specificity for intestinal muscles.
[685] references
[686]
[687]
[688]
[689]
[690]

权利要求:
Claims (31)
[1" claim-type="Currently amended] A compound having the formula (I) or a pharmacologically acceptable salt thereof:
Formula I

here,
A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and is bonded to its single ring carbon atom,
Ar is phenyl or heteroaryl having 5 or 6 ring groups,
R ₁ and R ₂ are independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R ₁ and R ₂ jointly form lower alkylenedioxy or optionally substituted benzo ,
R ' ₃ is (i)-(CH ₂ ) _n NR ₁₀ , R ₁₁ , n is 2 or 3 and each of R ₁₀ and R ₁₁ is lower alkyl or R ₁₀ and R ₁₁ are saturated azacyclo or To form an azabicyclo ring system; (Ii)-(CH ₂ ) _m -Q wherein m is 0 or 1 and Q is a saturated azacyclo or azabicyclo ring system bonded by its carbon atom,
Conditionally,
(i) A is cyclopropane unsubstituted or mono-substituted by lower alkyl or lower alkenyl, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ , R ₁₁ and R ₁₀ and R ₁₁ If it is lower alkyl, R ₁₀ and R ₁₁ together contain at least 6 carbon atoms;
(Ii) A is a cyclopropane ring, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ , R ₁₁ , n is 2 and R ₁₀ and R ₁₁ are pyrrolidine rings with nitrogen atoms When R ' ₃ is-(CH ₂ ) _m -Q, m is 0 and Q is a tropanyl ring, the cyclopropane ring is at least mono-substituted;
(Iii) if A is an unsubstituted cyclobutane ring, Ar is phenyl, and R ₁ and R ₂ are hydrogen, then R ' ₃ is diisopropylaminoethyl, diethylaminoethyl and N-methyl-4-piperi; Not a deal;
(Iii) when A is an unsubstituted cyclobutane ring, Ar is phenyl, R ₁ is hydrogen and R ₂ is p-methyl or p-methoxy, then R ' ₃ is N-methyl-4-piperidyl Not;
(Iii) when A is an unsubstituted cyclobutane ring, Ar is phenyl and R ₁ and R ₂ jointly form benzo, then R ' ₃ is not dimethylaminoethyl and diethylaminoethyl;
(Iii) when A is a cyclopentane ring and Ar is phenyl, the cyclopentane ring is at least mono-substituted;
(Iii) when A is an unsubstituted cyclohexane ring, Ar is phenyl, R ' ₃ is-(CH ₂ ) _n NR ₁₀ R ₁₁ and R ₁₀ and R ₁₁ are lower alkyl, then R ₁₀ and R ₁₁ are combined; Contains at least six carbon atoms; And
(Iii) If A is a cyclohexane ring, Ar is phenyl and R ' ₃ is-(CH ₂ ) _m -Q then the cyclohexane ring is at least mono-substituted.
[2" claim-type="Currently amended] A compound according to claim 1, wherein A is a group having the general formulas II, III, IV or V

Wherein R ₁ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, cycloalkyl, lower alkenyl, lower hydroxyalkyl, benzyloxy- Or lower alkyl, trifluoromethyl or hydroxy, or R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ jointly form lower alkylene, lower alkylenedioxy or oxo.
[3" claim-type="Currently amended] 3. A compound according to claim 2, wherein A is a group having formula II.
[4" claim-type="Currently amended] 4. A compound according to claim 3, wherein R ₁₀ and R ₁₁ together are lower alkyl having at least six carbon atoms.
[5" claim-type="Currently amended] The compound of claim 3 or 4, wherein at least one of R ₄ and R ₅ is not hydrogen.
[6" claim-type="Currently amended] A compound according to claim 1, wherein A is a group having general formula III.
[7" claim-type="Currently amended] The compound of claim 6, wherein at least one of R ₄ , R ₅ , R _6, and R ₇ is not hydrogen.
[8" claim-type="Currently amended] 8. A compound according to claim 6 or 7, wherein R ' ₃ is-(CH ₂ ) _m -Q, m is 0 or 1 and Q is a saturated azabicyclo ring.
[9" claim-type="Currently amended] 9. A compound according to claim 8, wherein m is one.
[10" claim-type="Currently amended] 8. A compound according to claim 6 or 7, wherein R ₁₀ and R ₁₁ together are alkyl having at least six carbon atoms.
[11" claim-type="Currently amended] A compound according to claim 1, wherein A is a group having formula IV.
[12" claim-type="Currently amended] 12. A compound according to claim 11, wherein R ₁₀ and R ₁₁ together are lower alkyl having at least six carbon atoms.
[13" claim-type="Currently amended] 2. Compounds according to claim 1, wherein A is a group having the general formula V.
[14" claim-type="Currently amended] The compound of claim 13, wherein at least one of R ₄ , R ₅ , R ₆ , R ₇ , R _8, and R ₉ is not hydrogen.
[15" claim-type="Currently amended] 15. Compounds according to claim 13 or 14, wherein R ₁₀ and R ₁₁ together are lower alkyl having at least 6 carbon atoms.
[16" claim-type="Currently amended] The method according to any one of claims 1 to 15,
Ar is phenyl, 2- or 3- thienyl, 2- or 3-furanyl or 2-, 3- or 4- pyridine; And / or R ₁ and R ₂ are independently hydrogen, fluoro, chloro, bromo, C _1-4 alkyl, C _1-4 alkoxy, methoxymethyl, phenoxymethyl, vinyl, allyl, trifluoromethyl; And / or
R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, C _1-4 alkyl, C _1-4 alkoxy, methoxymethyl, benzyloxymethyl, vinyl, allyl, trifluoromethyl Or else R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ are jointly dimethylene, trimethylene, tetramethylene or ethylenedioxy.
[17" claim-type="Currently amended] The azacyclo and azabicyclo ring according to any one of claims 1 to 16, wherein the azacyclo and azabicyclo rings are optionally substituted piperidine, pyrrolidine, azanorbornane, azacycloheptane, quinuclidin, isoquinuclidin, tro Pan, azabicyclo [3.2.1] octane, azabicyclo [2.2.1] heptane, 2-azabicyclo [3.2.1] octane, azabicyclo [3.2.1] octane, azabicyclo [3.3.0] octane, azabi Compounds characterized by being cyclo [3.2.2] nonane and azabicyclo [3.3.1] nonane.
[18" claim-type="Currently amended] A compound according to claim 1, wherein the compound is
-2-(diisopropylamino) ethyl 1-phenyl-2-trans-methoxy-methyl cyclopropanecarboxylate;
Quinuclindinyl 1-phenylcyclopropanecarboxylate;
-(Diisopropylamino) ethyl 1-phenyl-cis-2-methoxymethylcyclopropanecarboxylate;
-2-(diisopropylamino) ethyl 1 -phenyl-3 -dimethylcyclobutanecarboxylate;
-Quinuclindinyl 1-phenylcyclobutanecarboxylate;
-2-(diisopropylamino) ethyl 1 -phenyl-3 -cis-methylcyclobutanecarboxylate;
-(Diisopropylamino) ethyl 1 -phenylcyclohexanecarboxylate.
[19" claim-type="Currently amended] 19. A compound according to any one of claims 1 to 18, wherein the compound is for use as a therapeutically active substance.
[20" claim-type="Currently amended] A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, optionally together with a pharmaceutically acceptable carrier.
[21" claim-type="Currently amended] A method of treating a living body suffering from a disease associated with urinary incontinence, the method comprising administering to said living body an effective amount of a compound having Formula IA or a pharmacologically acceptable salt thereof:
Formula IA

here,
A is an optionally substituted cycloalkaline ring having 3 to 6 carbon atoms and is bonded to its single ring carbon atom,
Ar is phenyl or heteroaryl having 5 or 6 ring groups,
R ₁ and R ₂ are independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R ₁ and R ₂ jointly form lower alkylenedioxy or optionally substituted benzo ,
R ₃ is (i)-(CH ₂ ) _n NR ₁₀ , R ₁₁ , where n is 2 or 3 and each of R ₁₀ and R ₁₁ is lower alkyl or R ₁₀ and R ₁₁ are saturated azacyclo or azabi with nitrogen atoms To form a cyclo ring system; (Ii)-(CH ₂ ) _m -Q wherein m is 0 or 1 and Q is a residue of a saturated azacyclo or azabicyclo ring system bonded by its carbon atom.
[22" claim-type="Currently amended] A method of treating a living body suffering from a disease associated with irritable bowel syndrome, the method comprising administering to said living body an effective amount of a compound having Formula IA as defined in claim 21.
[23" claim-type="Currently amended] 23. The method of claim 21 or 22, wherein A is a group having the general formulas II, III, IV or V:

Wherein R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, cycloalkyl, lower alkenyl, lower hydroxyalkyl, benzyloxy- Or lower alkyl, trifluoromethyl or hydroxy, or R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ jointly form lower alkylene, lower alkylenedioxy or oxo.
[24" claim-type="Currently amended] The method of claim 21, 22 or 23,
Ar is phenyl, 2- or 3-thienyl, 2- or 3-furanyl or 2-, 3- or 4-pyridine; And / or
R ₁ and R ₂ are independently hydrogen, fluoro, chloro, bromo, C _1-4 alkyl, C _1-4 alkoxy, methoxymethyl, phenoxymethyl, vinyl, allyl, trifluoromethyl; And / or
R ₄ , R ₅ , R ₆ , R ₇ , R ₈ and R ₉ are independently hydrogen, C _1-4 alkyl, C _1-4 alkoxy, methoxymethyl, benzyloxymethyl, vinyl, allyl, trifluoromethyl Or else R ₄ and R ₅ or R ₆ and R ₇ or R ₈ and R ₉ are jointly dimethylene, trimethylene, tetramethylene or ethylenedioxy.
[25" claim-type="Currently amended] The azacyclo and azabicyclo ring according to any of claims 21 to 24, wherein the azacyclo and azabicyclo rings are optionally substituted piperidine, pyrrolidine, azanorbornane, azacycloheptane, quinuclidin, isoquinuclidin, tro Pan, azabicyclo [3.2.1] octane, azabicyclo [2.2.1] heptane, 2-azabicyclo [3.2.1] octane, azabicyclo [3.2.1] octane, azabicyclo [3.3.0] octane, azabi Cyclo [3.2.2] nonane and azabicyclo [3.3.1] nonan.
[26" claim-type="Currently amended] 23. A compound according to claim 21 or 22, wherein the compound having formula IA is
-2-(diisopropylamino) ethyl 1-phenyl-2-trans-methoxy-methylcyclopropanecarboxylate;
Quinuclindinyl 1-phenylcyclopropanecarboxylate;
-(Diisopropylamino) ethyl 1-phenyl-cis-2-methoxymethylcyclopropanecarboxylate;
-2-(diisopropylamino) ethyl 1 -phenyl-3 -dimethylcyclobutanecarboxylate;
-Quinuclindinyl 1-phenylcyclobutanecarboxylate;
-2-(diisopropylamino) ethyl 1 -phenyl-3 -cis-methylcyclobutanecarboxylate;
-(Diisopropylamino) ethyl 1-phenylcyclopentanecarboxylate;
Quinuclindinyl 1-phenylcyclopentanecarboxylate;
-(Diisopropylamino) ethyl 1-phenylcyclohexanecarboxylate; or
Quinuclindinyl 1-phenylcyclohexanecarboxylate.
[27" claim-type="Currently amended] A pharmaceutical composition for the treatment of diseases associated with urinary incontinence, comprising a compound having formula (IA) as defined in any one of claims 21 and 23-26, optionally together with a pharmaceutically acceptable carrier.
[28" claim-type="Currently amended] A pharmaceutical composition for treating diseases associated with irritable bowel syndrome (IBS), comprising a compound having formula (IA) as defined in any one of claims 21 and 23-26, optionally together with a pharmaceutically acceptable carrier.
[29" claim-type="Currently amended] Use of a compound having formula (IA) as defined in any of claims 21 and 23 to 26 for the manufacture of a medicament for the treatment of diseases associated with urinary incontinence.
[30" claim-type="Currently amended] Use of a compound having formula (IA) as defined in any of claims 21 and 23 to 26 for the manufacture of a medicament for the treatment of diseases associated with irritable bowel syndrome (IBS).
[31" claim-type="Currently amended] A process for the preparation of a compound having formula I as defined in claim 1 comprising:
(a) reacting a compound having the following formula (VI) or a reaction derivative thereof having a carboxyl group activated with a compound having the formula (VII) or a compound having the formula (VII) in the presence of a strong base;
Formula VI

Wherein R ₁ , R ₂ , A and Ar are as defined in claim 1
Formula Ⅶ
HO-R ' ₃
Where R ' ₃ is as defined in claim 1
Formula Ⅷ
Cl-R ' ₃
Where R ' ₃ is as defined in claim 1
(b) in the compound having the formula VII, converting at least one of A ', R' ₁ and R ' ₂ into groups A, R ₁ and R ₂ , respectively,
Formula Ⅸ

Wherein R ′ ₃ and Ar are as defined in claim 1, and A ′, R ′ ₁ and R ′ ₂ represent A, R ₁ and R ₂ , respectively, as defined in claim ₁ , or each A , Represents a group that can be converted to R ₁ and R ₂
If desired, the racemates obtained as optical isomers are separated and / or form acid addition salts with organic or inorganic acids.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US6054464A|2000-04-25|Azabicyclic esters of carbamic acids useful in therapy

---

EP0585328B1|2002-01-09|Substituted 3-aminoquinuclidines

---

CA2046429C|2003-09-16|Imide derivatives, and their production and use

---

US5096890A|1992-03-17|Pyrrolidine derivatives

---

AU720358B2|2000-06-01|Tropane-derivatives, their preparation and use

---

ES2329975T3|2009-12-03|muscarinic antagonists.

---

US4910207A|1990-03-20|Method of treating psychosis with N-quinuclidinyl-benzamides

---

CA2675669C|2015-05-26|Novel compounds

---

EP1638951B1|2008-02-13|Cyclohexyl sulphones as gamma-secretase inhibitors

---

AU613383B2|1991-08-01|Pro-drugs for oxadiazole muscarinic agonists

---

DE602004010829T2|2008-12-11|Adamantan and azabicyclooctanese and nonanderivates, process for their preparation and their use as dpp iv inhibitors

---

JP5745021B2|2015-07-08|Tropane compound

---

CA2086434C|1998-09-22|Quinuclidine derivatives

---

KR0165667B1|1999-01-15|Quinuclidines, their pharmaceutical use and process for their preparation

---

US5624947A|1997-04-29|Phenyl derivatives useful as tachykinin antagonists

---

EP1343761B1|2005-08-17|Piperidine mch antagonists and their use in the treatment of obesity

---

AU603564B2|1990-11-22|Oxadiazoles useful in the treatment of senile dementia

---

ES2213703T5|2011-11-02|Carbamates derived from arilalquilaminas.

---

ES2218418T3|2004-11-16|Azabiciclic carbamates and its use as an alfa-7 nicotinic acetilcoline receiver agonists.

---

EP0591333B1|1997-03-05|Azanorbornane derivatives

---

US6890936B2|2005-05-10|Muscarinic antagonists

---

DK170166B1|1995-06-06|N- | non-3-yl) -1-methylethylazole-3-carboxamide with 5-HT antagonist activity, pharmaceutical preparations containing the compound, a process for the preparation of the compound as well as its use as a pharmaceutical

---

US7998958B2|2011-08-16|Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors

---

US7365193B2|2008-04-29|Amino-substituted tricyclic derivatives and methods of use

---

EP2014285B1|2010-05-05|NPYY5 antagonists

同族专利:

---

公开号 | 公开日

---

IL128096D0|1999-11-30|

---

NO990335L|1999-03-29|

---

BR9710614A|2000-01-11|

---

AU3790597A|1998-02-20|

---

PL331384A1|1999-07-05|

---

CN1226886A|1999-08-25|

---

EE9900034A|1999-08-16|

---

CA2261692A1|1998-02-05|

---

EP0923536A1|1999-06-23|

---

US6124354A|2000-09-26|

---

AU724563B2|2000-09-28|

---

TR199900185T2|1999-04-21|

---

BG103207A|1999-10-29|

---

SK4699A3|2000-04-10|

---

JP2000515881A|2000-11-28|

---

WO1998004517A1|1998-02-05|

---

NO990335D0|1999-01-25|

---

NZ333798A|2000-08-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1996-07-29|Priority to SE9602888A

---

1996-07-29|Priority to SE?9602888-1?

---

1996-07-29|Priority to SE?9602887-3?

---

1996-07-29|Priority to SE9602887A

---

1996-07-29|Priority to SE9602889A

---

1996-07-29|Priority to SE?9602890-7?

---

1996-07-29|Priority to SE?9602889-9?

---

1996-07-29|Priority to SE9602890A

---

1997-07-23|Application filed by 존 헤덴스트룀, 파마시아 앤드 업존 에이비

---

2000-05-25|Publication of KR20000029703A

优先权:

---

申请号 | 申请日 | 专利标题

---

SE?9602888-1?|1996-07-29|

---

SE?9602887-3?|1996-07-29|

---

SE9602887A|SE9602887D0|1996-07-29|1996-07-29|Carboxylic esters, Their Use and Preparation|

---

SE9602889A|SE9602889D0|1996-07-29|1996-07-29|Carboxylic esters, Their Use and Preparation|

---

SE?9602890-7?|1996-07-29|

---

SE9602888A|SE9602888D0|1996-07-29|1996-07-29|Carboxylic esters, Their Use and Preparation|

---

SE?9602889-9?|1996-07-29|

---

SE9602890A|SE9602890D0|1996-07-29|1996-07-29|Carboxylic esters, Their Use and Preparation|